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Abstract 
Fibres show promising applications such as textiles, filtration, sensing and tissue 
engineering. In this study, an infusion gyration system to produce polymer micro and 
nano fibres with functions was introduced. By using this method, functional fibres can 
be formed from polymer solutions mixed with other functional materials.  
PEO or PVA water solution was used for making the spinning solutions. The 
fluorescence protein bound with gold nanoparticles was carried by the PEO water 
solution, from which the fibres assembled with protein were successfully generated 
through infusion gyration. A mixed molecular weight PVA combined water solution 
mixed with processed magnetic nanoparticles achieved fabrication of magnetically 
controllable fibres have the potential for drug release and its demonstration test 
showed a positive result.  
This spinning system provides control of the polymer solution flow rate during spinning 
which affects the fibre morphology such as average diameter and size distribution. 
The relationship between the spinning parameters and the product properties was 
studied for better understanding of the method. The analysis of infusion gyration and 
its fibre forming process was carried out.  
The fibres were characterised using several methods, such as optical microscopy, 
SEM, FTIR and UV-Vis, to establish the potential of infusion gyration and to confirm 
the functions of final fibre product.  
The infusion gyration system provides a simple micro and nano scale assembly 
approach to integrate different protein functionalities into nanofibres with potential 
applications. Magnetic PVA nanofibres are promising for drug delivery.  
  
4 
Impact Statement  
The work presented in this thesis introduces a novel commercially attractive fibre 
spinning method, uncovers a new fibre generating process and describes several 
functional fibre products made from using it.  
The infusion gyration fibre spinning system developed here could dramatically 
increase the value and flexibility of the fibre production industry and broaden the 
variety materials used to create products the fibre industry can offer. By combining the 
gyration spinning process and the solution inflow (infusion) system, both fibre 
productivity and structural dimensions can be managed. This system provides an 
effective way of fibre manufacturing at a relatively large scale. By changing the infusion 
rate of the polymer solution, it has been demonstrated that the average fibre size can 
be controlled within hundreds of nanometres and tuned for different applications. This 
means that designing a specific type of product is possible. 
The fluorescent protein integrated within polymer fibres made by infusion gyration 
show a strong signal of fluorescence which brings a promise of new biomaterials for 
the future imaging and sensing industry. This simple nanoscale assembly approach to 
incorporate protein(s) into polymer fibres proves that the protein(s) can be embedded 
on surface and sub-surface of the fibres. As the integration of protein(s) into polymer 
fibres keeps the material functioning well biologically, it can offer a fundamental 
platform in the design and fabrication of novel biomaterials which may be useful in 
medical treatments. 
The magnetic fibres respond quickly to a moving external magnetic field which is 
tested and shown to be effective in immobilization and triggered release of drugs. This 
material is biocompatible and remotely controlled. In the future, it can deliver particular 
drugs to the target which will be released with contactless actuation in clinical use. 
5 
To conclude, the infusion gyration system with its making of new products not only 
opens a gateway of fibre processing research for the laboratory and industry, but also 
provides a method for biomedical fibre design and generation in an acceptable time 
frame with a sufficient volume of material used in the future in clinics.  More parameters 
can be added, recorded and changed to the system for designing complicated 
materials. 
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Chapter 1.  
Introduction   
1.1 Background  
Polymer nanofibre is an excellent engineering material in various applications such as 
biomedical textile and tissue engineering because of its high surface-to-volume ratio1. 
The key factor is the diameter of polymer fibre which has to be in the sub-microns or 
nanometres (e.g. 10×10-3-100×10-3 µm) rather than micrometres (e.g. 10-100 µm)2. 
This factor gains flexibility in surface functionalities and superior mechanical 
performance as well in comparison with any other known material form. Over the last 
decade or so, a wide variety of techniques have been used to process nanofibres and 
nanofibrous structures such as drawing, template synthesis, phase separation, self-
assembly and electrospinning.  
In the fibre industry, drawing is a similar process to dry spinning for making very long 
single nanofibres one by one. However, drawing can only be used for a viscoelastic 
material due to its strong cohesion during pulling. The template synthesis uses a 
nanoporous membrane as a template to process solid or hollow shape nanofibres. 
Various raw materials such as electronically conducting polymers, metals, 
semiconductors, and carbons can be fabricated by this method but not for one-by-one 
continuous nanofibres. The phase separation process takes a relatively long time 
because it needs to transfer the solid polymer through dissolution, gelation and 
extraction (solvent, freezing, and drying) into nanoscale porous foam. The self-
assembly process also takes a long time to generate continuous polymer nanofibres 
by organizing individual, pre-existing components into desired functions and patterns. 
Thus, some researchers regarded electrospinning as a promising method of 
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generating continuous nanofibres from various polymers for mass production if it is 
fully developed. However, the yield of the electrospun fibres is relatively low and its 
long processing time cannot be ignored.  
In fact, the most common method in recent years of generating micro or nano fibre 
from polymer solution is electrospinning which requires high voltage during the 
process and this system has been studied for decades3. Moreover, the yield from the 
electrospinning process is low from several studies1. Centrifugal spinning is an 
alternative method for producing fibres rapidly with a high yield4. The spinning fluid 
from the rotating part comes out through nozzle tip(s) and forms solidified fibres from 
the fluid jet.  
Another method is a pressurised gyration system using high pressure gas and 
centrifugal force which has been proven to generate well-aligned fibres on a larger 
scale5. It has a relatively high yield of fibre production compared with solution blowing, 
etc. The solution is put into the vessel before spinning which requires both high rotating 
speed and high pressure gas. Despite the versatility of the process, pressurised-
gyration consistently produces a range of natural and synthetic polymers with 
controllable morphologies and functionalities in the submicron diameter range that is 
otherwise difficult to achieve by standard spinning methods. In a typical parametric 
plot of rotating speed and working pressure for a polymer solution to be spun, 
conditions can be obtained that determine the final product shape as either fibres or 
microbubbles6. Moreover, apart from solution physical properties, i.e. viscosity and 
surface tension, there needs to be a critical minimum concentration of polymer solution 
to initiate and produce continuous fibres, otherwise an architecture of beads results. 
A typical pressurised-gyration process consists of simultaneous centrifugal spinning 
and solution blowing where the combination of centrifugal force and the forces arising 
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due to dynamic fluid flow act against the surface tension force to generate fine fibres. 
Even though pressurised-gyration is a simple and robust process, it does not allow 
control of fluid flow through the fibre generating orifices where generally the infusion 
rate of the polymer solution influence fibre size, size distribution and morphologies of 
fibres spun.  
In the laboratory practice, it happens that the solution is sprayed out on the inner walls 
of the protection container not as fibres but as drops because the solution is kept in 
the rotating vessel during the acceleration stage. It means the solution comes out from 
orifices before the vessel reaches the fibre forming rotating speed. This becomes the 
main loss of making use of the polymer solution for spinning fibres.  
Therefore, the infusion gyration system was introduced in this study (Figure 1-1).  
 
Figure 1-1 Schematic diagram of the infusion gyration spinning process. 
It removes the gas pressure but connects to a syringe with a syringe pump (PHD 4400 
Programmable, Harvard Apparatus) instead. This system can control the polymer 
solution flow rate into the cylindrical vessel to prevent solution loss during the process. 
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Moreover, in some following test experiments, the flow rate factor was researched. It 
holds the ability to tune the average size of fibre. 
Functionalized hybrid fibre has potential applications such as bioengineering and 
biomedical technology7. For tissue engineering, especially scaffolds, biopolymers 
(aloe vera, silk fibroin and curcumin) have been incorporated into polycaprolactone 
(PCL) as suitable substrates to make fibres mimicking the functions of extracellular 
matrix. The protein, such as enzyme, has been tested to improve the activity retention 
and the dry storage stability using polymer nanofibres as carriers8. Functional fibres 
for releasing a protein drug (bioactive lysozyme) in a sustained manner over a one 
week period have been achieved by directly dissolving protein molecules in an 
electrospinning solvent medium and making biodegradable fibrous meshes using 
electrospinning9.  
In consideration of the advantages of assembling biomaterials into polymer nanofibres 
and to make full use of nanoscale material properties combined with bio-functions, the 
fluorescent protein has been selected in use to achieve functional polymer fibres by 
infusion gyration. The fluorescent protein holds great promise for biotechnology and 
cell biology10. The DsRed fluorescent protein is cloned from Discosoma coral which 
shows red fluorescence as well as the green fluorescent protein (GFP) from Aequorea 
jellyfish11. Due to the inner structure of the fluorescence protein, it has different 
excitation and emission wavelengths12. This special property of fluorescence protein 
was used in the mixture of the solution to generate functional fibres, i.e. fluorescent 
fibres by the infusion gyration system. The fluorescence protein used in this study is 
designed to bind to gold. Therefore, the gold nanoparticles were required to strengthen 
the fluorescence capacity for the final fibres. To demonstrate the potential of polymer 
fibres as a drug delivery platform, remote controllable composite fibres were made 
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through infusion gyration using PVA solution mixed with magnetic nanoparticles. The 
drug delivery test has been done to prove its potential of controlled release.  
 
1.2 Aims and Objectives  
The aim of this work is to investigate the whole process of making functional polymer 
micro and nano fibres using infusion gyration. PEO and PVA water solution was 
utilised and tested as the polymer solution. The fluorescence of the fibres was 
achieved by gold binding fluorescence protein and gold nanoparticles. Magnetically 
actuated PVA fibres mixed with magnetic nanoparticles will be made and tested for 
controlled drug delivery. The infusion gyration system will be tested to control the fibre 
size as outcome. The relationship between tuneable infusion flow rate and the final 
fibre size is going to be researched. Variable flow rate was tested and monitored for 
the fibre size comparison. SEM analysis is used to examine the fibre for the shape 
and even the fibre size distribution. EDX is used for element analysis in fibre. The 
characterisation is made by FTIR showing the existence of the protein or enzyme 
which also indicates the chemical bonding within the fibres. The function of the 
fluorescence protein bound with gold nanoparticles along polymer fibres needs to be 
tested in a working status. The fluorescence microscope is used to detect this function 
for the various fibre batches. The infusion gyration system is going to be researched 
more to gain the flexibility of adapting different polymer solutions as more polymers 
will be tested.  
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1.3 Structure of the Thesis  
This dissertation is ordered in chapters focusing on the infusion gyration process to 
generate functional polymer fibres along with different research work (Table 1-1).  
Chapter 1 introduces a brief background to polymer functional micro and nano fibres 
with the aims and objectives of this project.  
Chapter 2 reviews other researchers’ work including fibres materials, production 
methods and applications.  
Chapter 3 shows the whole technical details of the experiment for the study. Materials 
and methods are provided.  
Chapter 4 demonstrates the capacity of infusion gyration, for the first time, fabricating 
fibres. The infusion gyration method can generate micro and nano fibres that are 
integrated with inorganic binding peptides, namely, the well characterized gold binding 
dodecapeptide, Au-BP2, was used during the fibre formation process. It is 
demonstrated that the engineered peptide fibres have the capacity for controlling and 
directing the nanostructure assemblies. Fibre morphology is studied to detect the 
relationship between processing parameters and fibre size. Three different 
combinations of spinning solution are tested and the protein incorporation with final 
fibres is confirmed through several characterization methods. The bio-hybrid fibres 
could be further exploited to advance the peptide based materials for bio-fabrication 
of various protein arrays, plasmon-active nanoassemblies, bio-sensing and 
nanophotonic devices with controlled organization and architecture. 
Chapter 5 reports an efficient method for fabrication of composite microfibres that can 
be magnetically actuated and are biocompatible, targeting controlled drug release. 
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Aqueous solutions of polyvinyl alcohol (PVA), incorporated with citric acid coated 
Fe3O4 magnetic nanoparticles (MNPs), are subject to infusion gyration, to generate 
100-300 nm diameter composite fibres, with controllable MNP loading. The fibres are 
stable in polar solvents, such as ethanol, and do not show any leaching of MNPs for 
over 4 weeks. This material is effective in the immobilization of drugs demonstrated 
using acetaminophen as an example and achieves triggered release by a moving 
external magnetic field. Coupled with biocompatibility and lightweight property, this 
remote actuation ability of the fibres renders enormous potential for them to be used 
as a functional drug-release agent. 
Chapter 6 gives theoretical analysis of infusion gyration and shows its potential for 
other products.  
Chapter 7 brings a conclusion to the study and drafts a possible plan for future work.  
 
Chapter 1 Introduction with polymer fibre background as well as its 
generation methods. The aims and objectives. 
Chapter 2 Literature review of works from different researchers on micro 
and nano fibre generation. 
Chapter 3 Specification of experiments is illustrated in this chapter including 
materials used and methods. 
Chapter 4 Fabrication of PEO fibres with fluorescent protein using infusion 
gyration. 
Chapter 5 Fabrication of PVA fibres with magnetic nanoparticles for drug 
release. 
Chapter 6 Infusion gyration analysis. 
Chapter 7 This chapter covers conclusions and future work. 
Table 1-1 Structure of the thesis.  
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Chapter 2.  
Literature review  
2.1 Introduction  
2.1.1 Polymer-based nanofibres  
Polymer-based nanofibres have been investigated for a myriad of biomedical 
applications, including scaffolds for tissue engineering, materials for wound dressing 
and vehicles for drug delivery13. Polymer is a large molecule, or macromolecule, 
composed of many repeated subunits. They have complicated properties such as 
melting point, glass transition temperature and mixing behaviour. Even the same 
polymer has different average molecular weight. However, they have excellent 
performance in several areas better than metal or ceramics. For example, it has been 
reported that biomimetic aramid nanofibres with poly(vinyl alcohol) (PVA) composites 
can be used as load bearing soft tissues with ~9.1 MPa tensile moduli, ~325% ultimate 
tensile strains and ~26 MPa compressive strengths, superior to cartilage14. (Figure 2-1) 
 
Figure 2-1 A sample of aramid nanofibre with PVA 30 hydrogel with tensile strain (Scale bar: 10 mm), 
compressive load of 10 N (Scale bar: 30 mm) and tensile load of 10 N (Scale bar: 50 mm)14. 
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The amazing properties of polymer help people design special materials with functions 
such as self-healing reported15 (Figure 2-2). A 2-mm-thick rectangular sheet (10 mm x 
20 mm) was prepared by heating TUEG3 (a polymer synthesised from 1,2-bis(2-
aminoethoxy) ethane and 1,1’-thiocarbonyldiimidazole) to 140 °C followed by a natural 
cooling process.  
 
Figure 2-2 Self-healing of polymer material.15 
Then, to ensure smooth cutting, it was cut using scissors into two pieces under gentle 
heating by a dryer. These two pieces were tightly pressed together after 10 min cooling 
for 30 sec. Approximately 0.2 MPa stress was applied to ensure that their freshly cut 
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surfaces were brought into contact. The merged sheet can bear a tensile load of 300 
g indicating successful self-healing of TUEG3. 
Micro and nano scale fibres are of particular interest in biomedicine, as their 
morphology resembles biological tissue. They are also of high surface area and 
surface energy, and can be organized into porous hierarchical structures, which are 
highly desirable properties for cell and tissue adhesion, as well as the adsorption of 
drug molecules.  The physical structure of the fibres can be readily customized to 
adapt to different applications. Furthermore, materials used for fibre formation have 
been developed to facilitate the incorporation of fibres with biodegradable16,17 
antibiotic properties18 and even those that include living tissue19–21. Extensive progress 
has also been made in the scale-up of such materials targeting industrial 
applications22.  
 
 
2.1.2 Peptides  
Peptides, a material to be used in the study, are the molecular building blocks of the 
biological world and contribute to the astonishing range of physical, chemical and 
biological properties displayed by proteins23,24. Moreover, peptides play a key role in 
molecular recognition and self-assembly by offering compartmentalization within 
organic frameworks where different function(s) may be coupled24,25. Functional 
polymeric fibres are promising candidates to mimic these biological building blocks in 
designing flexible materials with hierarchical architecture.  
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However, fabrication of bio-hybrid fibres that mimic even the most fundamental level 
of hierarchical organization integrated with biological property has been challenging 
due to the lack of control between dissimilar phases, i.e. organic and inorganic phases. 
Engineered peptides with inorganic material recognition may be the unique building 
blocks to exert control over dissimilar nanophases and contribute to hybrid nanofibre 
formation with added functional properties inherent to the peptide.  
Inorganic binding peptides have attracted tremendous interest in the last decade, 
ranging from assembly of nanoparticles25,26 to oriented immobilization of proteins27–29 
as well as synthesis of inorganics30,31 to bio-functionalization of surfaces32–36. 
Previously, selection by combinatorial display methods was described for peptide with 
the ability to bind to inorganic materials37–40. Solid binding peptides have been shown 
to control the biological-material interface in different application. However, they have 
not been investigated in their capacity to design functional fibres where the peptide 
based self-assembly process may be regulated at the molecular level to nucleate 
architecture and establish an ordered nanostructure. Combinatorial-selected and bio-
informatically optimized peptides for their adsorption properties and role in surface 
binding were studied41–43.  
 
 
2.1.3 Magnetic nanoparticles (MNPs)  
Magnetic material is widely used to approach movement or action control of products. 
One of its applications contributing in medical treatment is reported that magnetic 
oculomotor prosthesis has been used as an implantation for a patient to recover44. 
This treatment simply makes use of the magnetic action force and requires surgery. 
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Another idea is to remotely control the movement of the magnetic target therefore to 
active functions without contact, such as hyperthermia therapy or bone regeneration 
scaffolds45. 
Magnetically triggered release of active pharmaceutical ingredients is a rapidly 
growing area of research with applications targeted towards efficient, minimally 
invasive pathways of drug delivery46–49. Such studies usually involve the use of 
superparamagnetic nanoparticles, which are either functionalized as drug-carriers50,51 
or incorporated with polymers to produce composites in the form of membranes52, 
liposomes53–55, protein microspheres48, gels52, etc. These materials have become 
highly significant in the advancement of diagnosis and treatment of cancer, and cardio-
vascular diseases, in addition to leading towards breakthroughs in regenerative 
medicine56–60.  
Polymer composites embedded with magnetic particles were made to achieve 
remotely actuatable materials which can be applied into soft robotic systems61 (Figure 
2-3).  
 
 
Figure 2-3 Soft robotic system61 
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The magnetic particles used are self-assembled in chains and directed by the 
magnetic field giving directional response. The folded accordion structures they made 
caused extension and compression when the magnetic field is applied. This 
engineered material provides noncontact control and shows great potential for soft 
devices.  
The magnetic component is typically activated via hyperthermia or for chemical signals 
to trigger the release of the drug62,63. Actuation of the drug-carrying platform by an 
external magnetic field (i.e., magnetic actuation), however, remains scarcely explored, 
but has enormous potential in biomedicine64,65. Such systems can potentially lead to 
remote-controlled, precise and safer pathways of drug delivery, and also pave the way 
to advances in the rapidly evolving field of micro-robotics, for applications in 
medicine65–67.  
Recent reports indicate that in vitro drug release, in particular, can be improved using 
conventional carrier such as mesoporous silica, in combination with magnetic 
nanoparticles (MNPs) for triggered cargo release68–70. Such carrier systems have 
great potential for treatment of cancer and other related diseases71. Many carrier 
systems need physical (e.g., thermal or light) or chemical (e.g., pH or red-ox changes) 
stimuli or enzymatic catalysis to initiate the release action, which require either 
invasive procedures or are limited in efficiency and controllability. However, the 
systems containing MNPs give rapid responses, with non-invasiveness, and can be 
easily controlled by external magnetic fields. MNPs also have the advantage of being 
easily integrated with organic components such as polymers to create composite 
materials with novel and improved capabilities56. Moreover, MNPs have been 
developed as imaging probes for magnetic resonance imaging (MRI) to visualize and 
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target disease when diagnosing56. Several parameters have been seriously 
considered such as physicochemical properties and nanoparticle surface 
modifications for improving the MNP performance in-vivo which has the potential for 
drug loading and release for clinical use. Magnetic polymer nanofibres draw attention 
for similar applications. Tube-shaped nanofibres with nanoparticles in the core were 
fabricated via coaxial electrospinning. They have magnetic behaviour after spinning 
either use PCL with FePt72 (Figure 2-4) or PET with Fe3O473, but no further concepts 
for application were reported or tested such as drug load. Also, it is difficult to obtain 
homogeneous dispersed Fe3O4 nanoparticles within polymer nanofibres via 
electrospinning74.  
 
Figure 2-4 The coaxial composite nanofibres (FePt in PCL) using electrospinning. (a) Transmission electron 
microscopy. (b) Scanning electron microscopy.72 
2.2 Methods for Fibre Production  
Micro and nano fibre producing have been researched in different areas and 
applications over decades. Many methods for fibre production, both in laboratory scale 
and industry, have been invented and improved. This section gives a brief review of 
different methods recently in use by researchers.  
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2.2.1 Electrospinning 
Electrospinning is popular for researchers to generate nanofibres in different fields 
such as chemical engineering and biomedical application75. As a conventional 
nanofibre generation system, a lot of work has been done to understand and optimize 
the process76. Figure 2-5 shows a typical experiment set-up schematic of 
electrospinning. The flow which is charged electrically comes from the nozzle and is 
accelerated by a high electric field77.  
 
Figure 2-5 Schematic diagram of a typical electrospinning setup77. 
Electrospinning is simple to use to generate micro or nano fibres for small-scale 
(laboratory scale) production. An external electric field is applied on the pipette tip 
(spinneret) and a polymer solution is charged to feed through it78. On the tip, the 
droplet is formed as a suspended cone (Taylor cone) because its surface tension is in 
equilibrium with the electric field76.  
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When the surface tension is overcome by the strong electric field, the droplet ejects a 
tiny jet from its surface to the collecting plate. In the jet stream, the solvent evaporates 
gradually during the spread of the tiny jet toward the collecting plate. A typical SEM 
image of PVA fibres spun by electrospinning is shown in Figure 2-679.  
 
Figure 2-6 SEM image of 7% (w/v) PVA nanofibres by electrospinning79.  
The nanofibre morphology and mechanical properties can be affected by electric field 
strength, solution properties (viscosity, elasticity, conductivity and surface tension), 
humidity and temperature. From the experience of electrospinning process control, the 
flow rate of the polymer solution has an impact on fibre size as well as the applied 
voltage which is the main parameter greatly affecting fibre formation and its final shape 
including size, surface structure and number of beads80 (Figure 2-7).  
 
Figure 2-7 Effect of the applied voltage (increasing from left to right) on the pendant drop (depicted in light 
grey) and the Taylor cone (depicted in dark grey) formation80. 
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At the tip of the needle or capillary, a pendant drop is formed with the Taylor cone 
coming along at lower applied voltages. However, the volume of the pendant drop 
decreases as the voltage is increased until this Taylor cone forms at the needle tip. 
The solution stream will be ejected from within the needle if the applied voltage is kept 
increasing further which results an increase in number of beads.  
The reduction of the solution viscosity would also result in fibres with beads along their 
length85. These formed beads may provide the anchorage for load transfer in some 
applications while using the fibres. However, the beads formation relies on a threshold 
value of viscosity.   
Parameter Effect on fibre morphology 
Applied voltage increasing  Fibre diameter decreasing initially, then 
increasing (not monotonic) 
Flow rate increasing Fibre diameter increasing (beaded 
morphologies occur if the flow rate is 
too high)  
Distance between capillary and collector 
increasing 
Fibre diameter decreasing (beaded 
morphologies occur if the distance 
between the capillary and collector is 
too short) 
Polymer concentration (viscosity) 
increasing 
Fibre diameter increasing (within 
optimal range) 
Solution conductivity increasing Fibre diameter decreasing (broad 
diameter distribution) 
Solvent volatility increasing Fibres exhibit micro-texture (pores on 
their surfaces, which increase surface 
area) 
Table 2-1 Effects of parameters on fibre morphology for electrospinning80 
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Table 2-1 shows a simple summary of relationships between the processing parameters 
and the fibre morphology of electrospinning which the study also indicates that the 
exact relationship differs for each polymer or solvent system80. Thus, the quantitative 
relationships which suit a wide range of polymer or solvent systems can be hard to 
determine. This, again, confirms that the whole system is very complicated. It also 
means the flow rate factor is very important during processing and the Taylor cone 
needs to be considered before the experiment which may apply to other methods 
sharing the same principle.  
Some factors contributing to the mechanical properties of the composite fibres apart 
from the material properties are surface texture, shape and orientation of fibre 
reinforcements85. To strengthen the matrix material, nanoparticles are also used in 
some studies as reinforcement. Polymeric based fibres are formed without further 
treatment which is, however, required for the ceramic and metallic based ones 
according to the fabrication experience. If the solution for electrospinning is made 
using volatile solvent, pitted and porous fibres may form. The main mechanism for 
forming pores and dimples on the fibre surface is phase separation which is induced 
by using liquid nitrogen between the residual solvent and polymer and by this way 
using volatile solvent can be avoided. Electrospinning fibres can deliver different drugs 
like antibiotics and protein because they are flexible in the selection of materials80.  
For the electrospinning process, the yield per spinneret with very small fibre diameters 
is extremely low81. This technique has been explored extensively to achieve hollow, 
core-shell and microparticle-encapsulated fibres82. Without limiting the raw materials, 
the electrospinning can be used to process particular materials, of which the range is 
relatively wide as studied83. However, one of the electrospinning’s limitations is that it 
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requires the use of high-voltage equipment which also leads to the restriction on the 
dielectric constant of the spinning solvent by its working principle84.  
Another technique developed for two phase solution spinning is coaxial 
electrospinning72,73 (Figure 2-8). The inner needle and outer needle provide different 
fluid to spin forming core structure fibres.  
 
Figure 2-8 Schematic diagram of a typical coaxial electrospinning set-up72. 
 
Figure 2-9 Transmission electron microscopy images of core structure nanofibres fabricated by coaxial 
electrospinning at core flow rates of (a) 5 μl/min, (b) 7 μl/min, and (c) 10 μl/min73. 
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The magnetic nanofibres were fabricated by PET as a polymer sheath encapsulating 
the magneto-rheological fluid as a core using this technique. To achieve this core 
structure and ensure the magnetic nanoparticles are uniformly dispersed in the core, 
the values of the core and sheath flow rate are crucial. At different core flow rates of 
the magneto-rheological fluid, the sheath flow rate was fixed at 5 μl/min and the mass 
ratio of solution was 1.5:1(Figure 2-9).   
 
2.2.2 Multi-jet electrospinning 
Multi-jet electrospinning system was designed to increase the productivity of nanofibre 
and its fibre cover area on the collector86. It shares the same mechanism with 
electrospinning but has more jets per spinning (Figure 2-10).  
 
Figure 2-10 Multi-jet electrospinning86.  
The set-ups of multi-jet electrospinning (Figure 2-11) show that the solution and 
grounded collector can be electrically charged in a different way serving different 
applications (Figure 2-11 A and B). A secondary electrode, for control purpose, can also 
be with an electrically charged solution and grounded collector86. A different number 
of jets were tested (2-16) by using PEO solution on this system86.  
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In another design of multi-jet electrospinning, several syringes are used as electrodes 
in parallel alignment to fabricate tissues with different fibre materials gaining more 
control on each flow of the spinning solution87 (Figure 2-12). For different material in 
each syringe, different flow rate can be set to control each fibre size or quantity fulfilling 
the blend design.  
 
 
Figure 2-11 Schemes of multi-jet electrospinning set-ups86.  
However, multi-jet electrospinning is more complicated than the single-jet process. 
One reason is the existence of repulsion among similarly charged solution jets. This 
should be considered for complex tissue architectures and high efficiencies87.  
For electrospinning, the fibre size is also influenced by the distance between the 
capillary tip and the collector which was introduced in the last section. Although this 
distance plays a smaller role rather than applied voltage or flow rate for 
electrospinning80. Normally, the fibre diameter decreases with this distance increasing. 
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Also, this distance affects the drying process of the polymer fibre which relates to the 
formation of beads along fibres.  
 
Figure 2-12 An experimental set-up for multi-jet electrospinning. HVDC, high-voltage direct-current power 
supply87. 
Moreover, collection is the last step of the whole spinning process (even for other 
spinning methods) before characterization which is important because the samples 
must be original and their transfer should cause minimum effect. A clean metal plate 
with or without film protection is needed as a stationary collector for electrospinning. 
However, different types of designed collector were also developed, such as a 
rotational collector (a rotating drum/disk)88, to fulfil a wide range of applications89. 
2.2.3 Rotary jet/Centrifugal spinning  
Rotary jet spinning, i.e. centrifugal spinning, is an efficient and rapid method to 
generate fibres on micro or nano scale at low cost4. The apparatus consists of a 
spinneret (perforated reservoir) which is connected to a motor (variable speed from 
4000rpm to 37000rpm) (Figure 2-13). The reservoir, which contains polymer solutions 
starts rotating and the jet of solution is ejected from a small orifice90.  
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Figure 2-13 Schematic of the centrifugal spinning device preparing polymer fibres91. 
A study shows a simple model for fibre formation by this approach (Figure 2-14): The 
set-up is shown in (a); The diagram in (b) is seen from the top view where a fibre is 
ejecting from the spinneret to the collector; Initiation of the jet is in (c) to (f); Images 
are captured in (d) to (f) demonstrating the jet from the spinneret where the green 
arrows indicate the end of the jet and the yellow arrows show orifice position; 
Elongation of the jet is in (g) to (j); In (d) to (f) and (h) to (j), S0 is 0.85 cm and scale 
bars are 0.42 cm; Solvent evaporation happens in (k); Fibre colour is an indication of 
the presence of solvent in the collected fibres, as solvent evaporates, fibre colour 
changes from red to blue as (l) shows. Colour evolution is consistent with the 
measured mass change of the spun fibres90.  
The jet is stretched by centrifugal force then the solvent evaporates. The fibres solidify 
from the jet travelling until it reaches the collector. The process controlling fibre 
diameter is dominated by the jet extension because most solvent evaporates after 
fibres have reached the collector plates. PLA solution with different weight 
concentrations were tested generating fibres using different experimental conditions92. 
Experiments of others using a spinning head (30mm in diameter) were carried out4.  
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Figure 2-14 Schematic of rotary jet spinning apparatus90.  
The final results of fibre diameters produced by rotary jet spinning can be affected by 
several factors such as solution concentration, rotational speed, nozzle diameter and 
nozzle-collector distance (Table 2-2) 4.  
 
Table 2-2 Fibre diameter statistics of PAN fibres by centrifugal spinning4.   
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With the increase of solution concentration or nozzle diameter, the fibre diameter 
decreases. However, the effect of speed shows opposite results. The nozzle-collector 
distance has a limited effect. The primary principle enabling the fibre formation process 
(centrifugal force) directly relates to the spinneret (motor) rotation speed (Figure 2-15) 
93. 
 
Figure 2-15 Solution spinning spinneret 93. 
This method works successfully with PCL/collagen94. Moreover, PAN/PMMA fibre was 
generated which is used for making carbon nanofibres95 as well as 
SiO2/polyacrylonitrile membranes for Li-ion batteries as a separator96.  As can be seen 
from Figure 2-15, metal fins were used for better collection of fibres.  
 
2.2.4 Electro-centrifuge spinning  
The electro-centrifuge spinning method combines centrifugal and electrical forces. 
With the control of viscosity of solution, voltage, rotation speed and the flow rate of 
exiting solution from nozzle, the fibre characterization results show great enhancement 
compared to electrospinning97. The schematic of the set-up is shown in Figure 2-16. A 
high voltage power is applied to a metallic cylinder (E in the figure, negative electrode) 
as fibre collector and the nozzle (positive electrode) which is mounted on a circular 
plate. The system can switch to centrifugal spinning if voltage is not applied.  
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Figure 2-16 Schematic diagram electro-centrifuge spinning of the set-up, (A) axle of rotation, (B) polymer 
solution container, (C) nozzle tip, (D) encircling cylinder, (E) collector and (F) polymeric jet.97 
The polymer solution flows through the nozzle and when the circular plate rotates, the 
solution jet forms. By using centrifugal force and electrical force, the solution becomes 
a jet at the nozzle exit and the jet is elongated thousands of times to be extremely thin. 
Long nanofibres can form by the solvent evaporation and be collected on the interior 
surface of the collector. This system controls voltage and flow rate (by changing the 
nozzle length) and the effects were studied during fabrication on nanofibre production 
and diameter98 (Figure 2-17). 
 
Figure 2-17 The effects of production.98 
Polymer nanofibre production was tested on this system by using solutions of PAN in 
DMF and Nylon in formic acid. This approach overcomes the low production rate of 
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electrospinning. Moreover, it is a powerful method for the spinning solution with 
extremely low viscosity97. 
 
 
 
2.2.5 Pressurised gyration  
The pressurised gyration system uses high pressure gas from a nitrogen cylinder and 
a high speed rotating vessel to generate micro and nano fibres which can deliver larger 
scale production5. The actual experimental set-up is shown in Figure 2-18. The main 
working part is a rotary cylindrical vessel (aluminium, 60mm in diameter and 35mm in 
height) which contains 20 orifices on its circumference. The bottom side of the vessel 
is attached to a DC motor which provides 10,000rpm, 24,000rpm and 36,000rpm 
rotating speed. The top cap of the vessel is connected to the pressure lead by a rotary 
joint. The pressure can be varied up to 0.3 MPa from the gas cylinder (N2). Aluminium 
foil is placed around the vessel as a fibre collector which can be replaced by other 
materials depending on the fibre materials. PEO water solutions were used on this 
system. Three concentrations were chosen based on the solution viscoelastic nature: 
5wt%, 15wt% and 21wt%. Lower concentration promotes bead formation5. 
 
Figure 2-18 (a) Pressurised gyration set-up. (b) Schematic diagram of the set-up. (c) Scanning electron 
microscopy image of the fibres produced by pressurised gyration5. 
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This approach provides fibres with average diameter 60-1000nm. The yield of fibres 
is much higher than with electrospinning. The relationship between fibre diameter and 
gas pressure/rotating speed is shown in Figure 2-19 5. 
 
Figure 2-19 The relationship between fibre diameter and working pressure/rotating speed 5.  
The Rayleigh–Taylor instability has been introduced as the explanation of forming 
fibres. The fibre formation in this process is the result of both centrifugal force from 
high rotating speed and the pushing force from the blowing gas.  
The combined force against the surface tension of the polymer solution forms the jet 
and stretches it out from the vessel orifices into a longer and thinner stream. Then the 
stream forms a solid dry fibre due to evaporation (Figure 2-18 c).  
For pressurised gyration, polymer solution selection mainly relates to its rheological 
properties, for example, the chain entanglement in the polymer solution99.  
By controlling the pressure delivered and the rotating speed, the fibre diameter could 
be tuned linearly as well as pore size on fibres. Figure 2-20 shows the SEM images of 
pore structure on fibres spun by pressurised gyration (with different solvents and gas 
pressure)100. Fibres were made using chloroform (C in the figure), dichloromethane 
(D) and ethyl acetate (E) at a working pressure of 0, 0.1, 0.2 and 0.3 MPa (0, 1, 2 and 
3 along with C, D and E in the figure), respectively.  
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Figure 2-20 Scanning electron microscopy images of PMMA fibres prepared using pressurised gyration100. 
The potential of pressurised gyration can be developed because it is reported 
generating even micobubbles6 (Figure 2-21). The effect of different parameters on 
bubble diameter was studied. Figure 2-21 (a) depicts the bubble diameter change at a 
gas pressure of 0.02 MPa with a variable rotating speed. Figure 2-21 (c) shows the effect 
of the gas pressure on bubble diameter at a constant rotating speed of 36,000 rpm. 
The optical microscopy images of the bubbles generated are shown in Figure 2-21 (b) 
(10,000 rpm & 0.02 MPa) and Figure 2-21 (d) (36,000 rpm & 0.1 MPa). The change of 
the bubble diameter at these two parameters is seen to be linear, generally.  
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Figure 2-21 Microbubble formation by pressurised gyration (NP is nanoparticle) 6.  
 
Moreover, the relationship between the product form (fibres or bubbles) and spinning 
parameter (pressure level and motor rotating speed) has been studied (Figure 2-22).   
As can be seen in the parametric plot, zone 1 has no bubbles and zone 2 has no fibres. 
Zone 3 with fibres generated has a boundary to zone 4 with bubbling which relates to 
the rotating speed.   
Furthermore, zone 5 is the fibre formable region for PVA solution only. This confirms 
that pressurised gyration has the features of processing synthetic polymer fibres, 
composite fibres and microbubbles.  
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Figure 2-22 The relationship between the product form and the spinning parameter6.  
For fibre collection with pressurised gyration, fins were also used. The fin collector is 
designed to collect fibres as a mat format101(Figure 2-23). As some fibres require a 
specific shape in large scale after spinning for a test or designed application, they need 
to be in the shape right after the spinning.  
 
Figure 2-23 The shape memory polymer fibres/mats prepared by pressurised gyration101.  
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However, due to the properties of some spinning material, these fibres as final spun 
product have less flexibility. For example, they can be fragile to form a mat or difficult 
to bend like a spring. Therefore, fins are used in this collector to keep all the fibres 
spun in a form. This collector works well with the pressurised gyration producing 
PLLA/PMMA composite shape memory fibres (Figure 2-23)101. The final product 
achieves a shape memory function proofing the reliability of fin collector.  
15 aluminium fins construct the fin collector (Figure 2-24). Several of them need to be 
removed when using around the motor because they block the path of the crank part.  
 
Figure 2-24 Fin collector. 
Aluminium is light-weighted for use, and with well mechanical machining property, it is 
easy for manufacturing and repairing (part replacing). The fin’s dimension is 
2.5mm×30mm×300mm forming an angle of 80 degree to the horizontal plane with a 
10mm gap to each other from the bottom. The round base is 2.5mm thin with a 
diameter of 200mm. 
It is suitable for fibres formed as mat along the metal fins. However, the short distance 
to the orifices restricts some polymers because they may require more space for the 
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solvent to evaporate. Moreover, it is very hard to clean as can be seen in Figure 2-24. 
Therefore, different polymers may mix together on its surface causing impurity of the 
samples.  
 
 
2.2.6 Pressure driven spinning  
The pressure driven spinning process was devised to overcome the hazards and 
limitations of the electrospinning system such as the requirement of high voltage which 
may not be available in some circumstances102. The main parts of the device are 
stainless steel medium bore needles and the autoclavable chamber. The inner bore 
diameter of the needle varies from a few micrometres to several hundred micrometres. 
The needle is connected to a pressure chamber constructing a coaxial structure which 
has six exit orifices around the protruding needle on the surface. The mechanism of 
spinning microscale or nanoscale fibres on this device is to apply the pressure (0-0.6 
MPa) to the chamber and the flow rate to the needle. 
 
Figure 2-25 The pressure driven spinning process device102. 
Figure 2-25 is shown of the method at the working status of fibre spinning. A syringe 
pump is used for syringing the prepared solution into the single needle device. The 
Chapter 2 
57 
pressure applied to the chamber provides a pressurised by-pass flow through its exit 
orifices102. 
Different polymers have been tested fabricating composite fibres by this system such 
as PEO, PCL, PVA and PLLA. Several have porous texture on their surface. PEO 
solution was used with different concentrations and with nanosuspensions mixed 
(SiO2 nanoparticles and multiwalled bamboo-type nanotubes). The fibre size varies 
from 35nm to 387nm102. The parameters affecting the controlled fibre formation have 
been investigated. The functional materials generated through this method can be 
applied to the biomedical area.  
 
2.2.7 Solution blowing 
Figure 2-26 shows the schematic diagram of the solution blowing apparatus which 
utilises high-velocity gas flow as the force to drive polymer solution into fibres103.  
 
Figure 2-26 Schematic of the solution blowing apparatus103. 
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An annular nozzle used as a single nozzle spinning die is coaxially surrounded by a 
gas cavity (Figure 2-27). The peristaltic pump controls the polymer solution supply. The 
compressed air goes to the air cavity controlled by the pressure regulator. The stream 
of gas flow blows the polymer solution stream into fibres when the solution is ejected 
out of the nozzle tip. A heating unit is equipped to heat the air within the spinning 
cabinet to accelerate the evaporation of solvent. The exhaust blower under the 
collector removes air from the evaporated solvent. Cellulose nanofibres (260-1900nm 
in diameter) were successfully made using this method103. Coaxial structure fibres 
were achieved through blowing cellulose solution (as a core) and PEO solution (as a 
shell). This set-up uses mesh-like collector103. 
 
Figure 2-27 Solution blowing process84.  
Furthermore, if the polymer solution or even the polymer material without solvent (like 
a power) requires high temperature to heat or melt, the solution supply needs to be 
modified as well as the nozzle for some instance. A melting system, for example, has 
been introduced into the blowing system to melt and generate fibres which sometimes 
is also called the melt blowing method. Unlike the solution blowing method described 
above which normally requires room temperature for the polymer solution, a polymer 
melt is extruded through an orifice die during melt blowing. The melt with a jet is drawn 
by the hot air at the same temperature as the molten polymer.  
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Figure 2-28 Schematic of the die used in the melt blowing method. (a) Sectional views of the die. (b) End-on 
views of the two parts 104.  
The equipment reported has a v-slot form which supplies two air streams (Figure 2-28). 
Melt blown PS, PP, and PBT micro/nano fibres (average diameters ≤ 500nm) were 
made through this method104. 
 
 
2.2.8 Pull spinning   
Pull spinning apparatus consists of a high-speed rotating bristle which dips into a 
polymer or protein reservoir and pulls a droplet from the solution into a 
nanofibre105(Figure 2-29). The figure shows the schematic of the pull spinning method. 
From the side view illustration of a fibre, it is seen that the red arrow indicates the 
location of the bristle/fibre interface as well as the green one points the nozzle location.  
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Figure 2-29 Schematic and products of the pull spinning system105. 
Moreover, a fibre formed throughout one revolution is represented by the dashed white 
line. A nonwoven network would be formed by a multiple layer collection of fibres. Its 
composition can be adapted to multiple applications as well as the orientation. As a 
rapid fibre manufacturing platform, textile design is showed. The system uses two 
posts for fibre collection.   
 
2.2.9 Pressure coupled infusion gyration  
After the infusion gyration was invented which will be explained in details in Chapter 
3, a T-junction was used to combine the gas pressure and the flow rate into gyration 
system, i.e. pressure coupled infusion gyration106 (Figure 2-30).  
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Figure 2-30 Schematic diagram of the pressure coupled infusion gyration equipment106. 
The collection is also studied by this method that the collecting distance affects the 
fibre shape106.  
A squirrel-cage has been designed and used to help collect the fibres in a round format 
which is easier to clean because the smaller size fits the cleaning container with water 
or other solutions (Figure 2-31).  
 
Figure 2-31 Squirrel-cage collector schematic. 
A different concentration of PEO-water solution has been tried as well as pressure, 
rotation speed and flow rate to test the system to map the parameter relationship 
(Figure 2-32, Figure 2-33). 
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Figure 2-32 Combined effects of the flow rate and the pressure on mean fibre diameter106. 
 
Figure 2-33 Combined effects of the flow rate and rotation speed on mean fibre diameter106. 
It is noticed that there is a drop of mean diameter at the flow rate of 3000 µL/min which 
happens for different concentrations of PEO-water solution. This was also observed 
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with infusion gyration showing the complexity of the gyration-serious system which 
needs will be fully discussed in Chapter 4 and 6.  
 
2.2.10 Summary  
From the review of fabrication methods above, the same principle and procedure are 
shared by many which are pulling of the solution stream into a thinner one to be fibre. 
This driving force for the electrospinning process which is more widely used is from 
the strong electric field generated by the high voltage applied, however, the gyration 
and blowing process apply centrifugal force and gas pressure, respectively. A 
comparison study of methods has been done by other researchers107 (Figure 2-34).   
 
Figure 2-34 A concise comparison of fibre spinning processes107. 
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The materials used for fibre formation have been developed to facilitate the 
incorporation of fibres with biodegradable16,17, antibiotic properties18 and even those 
that include living tissue19–21. Extensive progress has also been made in the scale-up 
of such materials targeting industrial applications22. Despite the wealth of research 
conducted, such micro or nano fibres have not yet, however, made it to the clinical trial 
stage of biomedical applications. This can be attributed to multiple factors, from mass 
production to long-term stability of the fibres in-vivo. For example, electrospinning, 
which is the main synthesis method of fibre formation, poses many challenges to their 
sustained usage in medical applications. Solution polarity needs to be concerned as 
its principle uses an electric field to drive the jet92. The lack of control over fibre 
diameter and pore sizes, as well as the random, non-woven nature of the fibres 
produced, cause difficulty in cell-penetration, which is a key factor in sustained use of 
scaffolds for tissue engineering108,109. While electrospinning is effective in producing 
microscale fibres, smaller diameters are difficult to obtain110. Attempts at customizing 
fibre morphology via this technique are complicated and lead to lower yields111. 
Moreover, electrospun fibres have inherently weaker mechanical strength than cast 
fibres and the solvents and cross-linking agents involved in the process often lead to 
toxicity and non-compatibility in biological systems112.  
Alternative spinning techniques have been developed to counteract some of the 
drawbacks of electrospinning113. These, however, are not without flaws themselves. 
For example, electrospinning has a needle clogging problem for some polymer 
solutions which is not observed with pressurised gyration114.  
Biospinning is a technique suitable for producing fibres with greater mechanical 
strength, such as scaffolds for tendons or bones115. Nevertheless, this method is 
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hampered by high cost, difficulty in scale up, longer production times and lack of 
customizability. Meltspinning can create fibres by extruding a heated polymer through 
a spinneret with textural-control for cell applications116,117. Yet, high energy costs, 
expensive equipment and difficulty in producing cell-incorporating fibres are 
considerable impediments. The latter issue can be solved via an interfacial 
complexation process, to encapsulate cells, which is also cheaper118; despite this, 
limitations in scale up, materials and dimension control are significant disadvantages. 
Overall, a technique to produce such biocompatible fibres in a facile, fast, and cost-
effective manner, with controllable sizes and the potential for scale up, is highly 
desirable. If the above is also coupled with the ability of remote actuation, it can lead 
to significant advancements in drug delivery and tissue engineering.  
 
 
2.3 Controlled Drug Delivery by Fibres 
In recent years, drug delivery has been researched making significant progress for 
clinical use. Different kinds of materials have been studied and tested for better 
performance. This includes improving the drug volume load and controllable release. 
For the controlled part, it separates into trigger mechanism (switching on and off) and 
release rate adjustment. Researchers use specific material and innovative methods to 
develop drug delivery systems with different condition response. A large part of the 
systems is polymer based with pH-responsive control119, temperature control120, 
ultrasonic control121 or magnetic control122.  They produced gel beads123 or bio-film124 
to load more drug. Some research uses porous material, having a better capacity for 
absorbing particles, as a scaffold to carry and release drugs125.  
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Fibre in micro or nano scale is excellent material for loading drugs because of its 
extreme high surface-to-volume ratio1. One has been reported being used for lowering 
the environmental pollution. This nanocomposite is designed to release herbicide 
particles by temperature enhancing the utilization efficiency126.  
 
Figure 2-35 (a) Schematic of conventional pressurised gyration rig. (b) Schematic of modified rig to deposit 
fibres on meshed metallic discs for making filters.127 
Some use electro-spun copolymer fibre mats for wound dressing like curing burn 
skin128. For other purposes, antibacterial fibres with special nanoparticles were 
successfully produced127(Figure 2-35). However, without control function, it still has 
limited applications. To achieve this, movement controllable material is introduced as 
promising materials in a lot of areas. Some research shows active polymer film moving 
like waves driven by light129 (Figure 2-36). Except for the design of movement control, 
many polymers have been researched to use for drug release130. That somehow 
confirms the potential of polymers which is safe for the human body and capable of 
delivering drugs as well. A comparison of electrospinning and pressurised gyration for 
drug release study using Amphotericin B and itraconazole loaded PVP fibres 
concludes that the pressurised gyration is a promising method with rapid production 
of fibres compared to electrospinning114 (Figure 2-37).  
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Figure 2-36 Mechanism of wave propagation and parameters that influence the propagation speed129. 
 
Figure 2-37 Drug dissolution profiles a) Itraconazole-loaded fibres and b) amphotericin B fibres114.  
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Chapter 3.  
Experimental details   
3.1 Materials  
All reagents and chemicals were used as received, without further modification. The 
information of materials and suppliers are provided.  
 
3.1.1 Polyethylene oxide  
Polyethylene oxide (i.e. PEO) is a non-ionic homopolymer of ethylene oxide units with 
CH2CH2O. It is biocompatible with extreme low toxicity and commonly used in the food 
and pharmaceutical industry.   
 
Figure 3-1 Chemical structure of Polyethylene oxide.  
PEO was chosen to dissolve in water as the base spinning polymer solution regarding 
its safety (for the engineered protein to be used in the experiment) and well fibre 
formation by gyration such as pressurised gyration from the literature review.  
Polyethylene oxide (PEO, powder, molecular weight: 200000 g/mol) from Sigma-
Aldrich (Poole, UK) was used. To find the suitable PEO concentration of its aqueous 
solutions to spin by infusion gyration, 5%(wt), 10%(wt), 15%(wt) and 21%(wt) PEO-
water solutions were tried and studied.  
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3.1.2 Poly(vinyl alcohol)  
Poly(vinyl alcohol) (i.e. PVA), linear formula (C2H4O)X , is a water-soluble synthetic 
polymer which is ideal bio-material reported being used in food and medical 
applications. It is often used to form thin films or as a surfactant, but due to its 
rheological property, it is rarely spun into fibres by gyration series approaches.  
 
Figure 3-2 Chemical structure of Poly(vinyl alcohol).  
In this study, three types of PVA polymer powder, with different molecular weights, 
were obtained from Sigma-Aldrich (Gillingham, UK): (1) PVA (363170, Mw 13,000-
23,000, 87-89% hydrolyzed), (2) PVA (363138, Mw 31,000-50,000, 98-99% 
hydrolyzed), (3) PVA (363065, Mw 146,000-186,000, 99+% hydrolyzed).  
3.1.3 Fluorescent gold binding fusion protein  
Fluorescent proteins (DsRed_AuBP2, MBP-DsRed-AuBP2 and GFPuv-AuBP) are all 
made from Bioengineering Research Center (BERC), Department of Mechanical 
Engineering, University of Kansas (KU) (Lawrence, KS 66045, USA). To easily track 
the integration of Au-BP or Au-BP2 (with sequences WAGAKRLVLRRE or 
WALRRSIRRQSY) peptide into the polymer fibres, the gold binding peptide is 
genetically conjugated to a biomarker protein, i.e. red/green fluorescence 
(DsRed/GFPuv). The resulting protein with gold binding peptide tag (DsRed-AuBP2, 
MBP-DsRed-AuBP2 or GFPuv-AuBP) is hypothesized to blend into fibre formation by 
providing well-defined organic-inorganic surface interactions to decorate gold 
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nanoparticles embedded along the fibres while keeping its biological function, i.e. 
fluorescence property, intact.  
 
3.1.4 Gold nanoparticles  
Gold nanoparticles (average particle size: 10nm in diameter, stabilized suspension in 
0.1mM PBS, reactant free) used for binding the peptide from the fluorescent proteins 
are from Sigma-Aldrich (Poole, UK).  
 
3.1.5 Magnetic nanoparticles 
Fe3O4, iron oxide, is a natural magnetic material which has strong magnetism and low 
toxicity. Its other forms, particles for example, keep the same magnetic property which 
is to be utilized in this study (fibre drug release part) for remote actuation and mobility 
control. If the iron oxide particle is within nano-size as that used in the experiment, it 
has the potential for embedding in nanofibres. The Fe3O4 magnetic nanoparticles 
(20nm, average diameter), i.e. MNPs, which were used are from US Research 
Nanomaterials, Inc. To prevent agglomeration, citric acid (Sigma-Aldrich, ACS grade 
>99.8%) has been used to process the particle powder.  
 
3.1.6 Acetaminophen 
Acetaminophen (analytical standard, powder) was purchased from Sigma-Aldrich 
(Poole, UK) which is an analgesic drug widely used to moderate pain in treatment. Its 
linear formula is CH3CONHC6H4OH and the molecular weight is 151.16.  
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Figure 3-3 Chemical structure of Acetaminophen.  
It was chosen as a model drug for this study due to its high solubility in ethanol131 and 
its characteristic UV-Vis absorption132. The acetaminophen powder is to be loaded on 
to the PVA-MNP fibres for release study with or without magnetic actuation.  
 
3.2 Preparation Methods 
3.2.1 Protein expression and purification  
The pDsRed-Monomer expression vector (Clontech) was used for cloning and 
expression of the dsred gene in Escherichia Coli 2507 (E. coli 2507) cells. Both the 
coding sequence of DsRed and Au-BP2 peptide were inserted into the pMal-c4x vector 
(NEB) to obtain MBP-DsRed-AuBP2 protein. The cells harbouring the expression 
vector were cultured in LB (Luria-Bertani) medium (10 g/L tryptone, 5 g/L yeast extact 
and 5 g/L NaCl, pH 7.0) supplemented with 100 µg/ml ampicillin. The cells were grown 
at 37oC to an optical density of 0.6 at 600nm at which point the protein induction was 
initiated by the addition of IPTG (Isopropyl β-D-1-thiogalactopyranoside, Sigma-
Aldrich, Milwaukee, WI) (0.4 mM) and for 48 h incubation.  
Following the expression of protein, cells were harvested by centrifugation at 4000 ×g 
(times gravity) for 30 minutes at 4 oC. The centrifuged cell pellet was re-suspended in 
column buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, pH 7.4) and disrupted by 
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sonication at 200 W for 1.5 min (pulsed on/off 10 s each) using Branson Digital Sonifier 
with a double stepped micro-tip. Cell debris was removed by centrifugation (15000 ×g 
for 30 min at 4 oC) and the supernatant was collected. The supernatant was sterile 
filtered as crude extract and 10 mL was loaded onto an amylose resin (New England 
Biolabs, Ipswich, MA) column (2.0 × 15 cm) equilibrated with column buffer. Following 
the removal of the unbound proteins, MBP-DsRed-AuBP2 fusion protein was eluted 
from the column with elution buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 10 
mM Maltose, pH 7.4). Next, the maltose binding protein (MBP) tag was cleaved and 
removed (detailed procedure given below). The fusion protein was analysed by SDS-
PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) on a 4 % 
stacking gel and 12 % separating gel. Gels were stained with Expedeon Instant Blue 
(Expedeon Inc., San Diego, CA) solution for 15 min at ambient temperature (20±1 oC) 
and destained with de-ionized water for 10 min.  
The fusion of the gold binding peptide, AuBP2, to the full-length DsRed-Monomer 
protein was accomplished using complete gene synthesis. A MBP tag was used to 
facilitate protein purification. To construct the fusion proteins and expression vector, 
an exoproteolytic restriction site was localized between the malE gene and N-terminus 
of fusion protein for subsequent cleavage using Factor Xa protease enzyme. The 
desired vector was created by designing the oligonucleotides and their primers based 
upon the known AuBP2 peptide sequence, “CGP-WALRRSIRRQSY-GPC”, with the 
addition of a spacer sequence, “SGGG”, inserted between the peptide and the DsRed-
Monomer on the expression vector (Figure 3-4). DsRed-AuBP2 encoding gene was 
cloned into the expression vector, pMALc-4X, harbouring malE gene. Next, the 
pMALc-4X-DsRed-AuBP2 plasmid was transformed into E. coli 2507. The transformed 
cells were used to express and purify the multifunctional proteins using an MBP-tag 
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which was later cleaved from the DsRed proteins by Factor Xa proteolytic enzyme. 
Further purification was accomplished using copper chelating affinity chromatography 
to remove the cleaved MBP tag and DsRed proteins (Figure 3-4). 
 
Figure 3-4 Vector Design and Expression of DsRed-AuBP2 protein. (a) Functional domains of the engineered 
protein, DsRed protein combined with gold binding peptide through a spacer, (b) Schematic of vector 
construction, (c) SDS-PAGE result of DsRed-AuBP2 following the affinity column purification.  
Purified proteins yielded a maximum red fluorescence when the protein was excited 
at 556 nm which follows the expected excitation and emission maxima of the DsRed-
Monomer at 556 nm and 583 nm, respectively. The gold binding affinity of the fusion 
protein was also confirmed through AFM analysis carried out on a gold surface.  
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The engineered fusion protein contains two functional domains of red fluorescent 
protein (DsRed) combined with a highly specific AuBP2 peptide tag (Figure 3-4 a). The 
pMALc-4X expression vector that encoded the maltose binding protein (MBP) was 
chosen due to its ease of cloning, over-expression, and purification. The DsRed-
AuBP2 gene was cloned into pMALc-4X expression vector and transformed into an 
expression host cell, Escherichia coli ER2507 (Figure 3-4 b).  
Positively identified clones were induced with 0.3 mM IPTG concentration to 
encourage over-expression of the DsRed-AuBP2 protein at 30 oC for 48 h. The 
expressed proteins were purified by applying two different column chromatography 
techniques. First, MBP-tagged affinity chromatography as used to purify MBP-DsRed-
AuBP2. Pure protein fractions containing MBP-DsRed-AuBP2 were concentrated to 5 
mg/ml of volume by 10000 MWCO of Amicon Ultra-15protein centrifugal filter (Merck 
Millipore, USA). Then, protein samples were transferred into 1X cleavage buffer 
containing 20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl2 (pH 8.0) by ultrafiltration using 
the same centrifugal filter tube. 40 μl of 1 mg/ml Factor Xa (New England Biolabs, 
USA) was added to 2.5 mg/ml of fusion protein in 1X cleavage buffer. The cleavage 
reaction was performed overnight at 16 oC. The second affinity chromatography 
technique was used for further purification of the DsRed_AuBP2 bifunctional protein.  
The red fluorescent protein, DsRed, has a unique binding affinity for copper ions, 
therefore a copper chelating affinity chromatography was utilized for the final 
purification step. On the basis of this interaction, the purification method was 
performed using copper immobilized column to remove unbound MBP- tags as well 
as Factor Xa enzymes following the cleavage reaction. As the crude protein was 
passed through the copper immobilized column, DsRed-AuBP2 bound to the resin 
whereas other interfering proteins did not bind to the column and hence were removed. 
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DsRed-AuBP2 was eluted using a competitive ligand imidazole that binds strongly to 
copper ions within the column, displacting our purified protein. The purity of DsRed-
AuBP2 was analysed by SDS-PAGE and gave a single sharp band for DsRed-AuBP2 
(Figure 3-4 c).  
 
3.2.2 PEO-protein(+Au NPs) solution  
All reagents were used without further purification and buffers were filtered and 
degassed before using. The polymer solution was prepared in an air-tight bottle using 
de-ionised water as solvent to dissolve the PEO powder under magnetic stirring at 
ambient temperature (20±1°C) for at least 24 hours until powders are well dissolved. 
Solutions with various concentrations of PEO were prepared, however, the 10wt% of 
PEO solution was used to integrate the proteins.  
Phosphate buffer saline (PBS, BioPerformance certified, pH 7.4, Sigma-Aldrich, 
Poole, UK) solution with a pH~7.4 was prepared at ambient temperature and added 
to the prepared MBP-DsRed-AuBP2 engineered protein (molecular weight ~73 kDa) 
using a micropipette. Adding 410 µl of PBS solution to the protein in the tube achieved 
a working stock solution (410 µl) of 50 µM (micro molar) protein. 50 µl concentrated 
gold nanoparticle solution which was added to the gently shaken protein solution.  
40g of PEO solution was taken in an air-tight bottle and 0.4 ml of the gold nanoparticle-
protein mixture was added while sonicating in a water bath using an ultrasound sonifier 
(Branson sonifier 250) at a power output of 60% for 15 minutes. This prevented 
aggregation in the gold nanoparticle-protein-polymer solution.  
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3.2.3 PVA-MNP solution  
Three types of PVA polymer powder with different molecular weights were taken in the 
following weight ratios to obtain three viscous solutions (Table 3-1)  
PVA type Molecular weight Weight % 
 
1 
 
13000 – 23000 
 
22 
2 31000 - 50000 10 
3 146000 - 186000 7 
Table 3-1 Molecular weights and weight ratios of PVA polymers used for fibre fabrication.  
The three solutions were made by mixing in the relevant weight of each type of PVA 
powder with distilled water and heating under magnetic stirring at 90 °C (for faster 
dissolution), for 5h, to achieve homogeneous mixtures. 
Next, the three solutions were mixed in a volume ratio of 1:1:1, to make a total of 30 
ml of 7.3wt% (type 1), 3.3wt% (type 2) and 2.3wt% (type 3) PVA aqueous solution. 
This mixture was magnetically stirred at the ambient temperature (~23 °C) for 24 hrs 
and then stored in sealed glass vials until use.  
This specific combination, which delivers the optimum output of PVA fibres for infusion 
gyration, was studied and then fixed through attempting a different mixture of polymers 
with a different ratio in experiment practice. The Individual PVA aqueous solutions of 
each molecular weight were tried at the early study of material selection and 
preparation which hardly generate fibres while spinning.  
To research the limitation of infusion gyration spinning capacity for a different polymer 
system, PVA was considered for fabrication as a kind of polymer which is still water-
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soluble but not dissolving too quickly as PEO which was tested and used for carrying 
protein (requiring non-toxic solution condition). However, PEO powder can dissolve in 
water at the ambient temperature (~23 °C) fast and, for the PEO fibres made, the 
dissolution is even faster in practice. The stability of fibres sometimes plays an 
important role because it decides the product application. In contrast, the PVA 
aqueous solution requires a higher temperature to dissolve the polymer powder well 
and completely, which may have a stronger resistance to humidity and act as a smooth 
shifting attempt of the polymer system for infusion gyration promising a change to a 
non-water-soluble one in the future. Moreover, the MNPs to be loaded in the next step 
have fewer requirements of solution condition than protein and PVA has been used 
generating fibres by other researchers (see Chapter 2), for example, through 
pressurised gyration6.  
To fulfil the appropriate viscosity of solution for spinning, a different concentration was 
tried. However, each of the solutions had negative results of fabrication which also 
had been the reason for attempting different molecular weight PVA polymers. The 
higher the molecular weight of PVA is, the more viscous the solution at the same 
concentration (weight%) would be and the longer time it takes to fully dissolve the PVA 
powder from the experimental preparation experience. As individuals with different 
molecular weight, they cannot spin into fibres themselves which have been tried many 
times, so the idea of combining them came up from the successful experience of 
fluorescent protein integration onto PEO fibres (see Chapter 4). The smaller protein 
structure can attach on the long chemical chain of PEO polymer in solution as well as 
in final fibres. Therefore, the different molecular weight PVA polymer with different 
chain length in chemical structure may offer a similar mechanism of nano-scale 
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assembly which can be used to strengthen the connection between each other and 
further to form fibres. 
Each specific molecular weight PVA was made into its aqueous solution first. The 
solution mixture of all three molecular weight types was tried which developed to the 
combination used for loading MNPs at ratio listed. However, during the trial, any two 
types from the three selections mixed to each other (three mixture varieties tested in 
total) were abandoned because of low fibre yield. Prior to putting MNPs into PVA for 
mixing, MNPs were subject to acid coating which is a nanoparticle aggregation 
prevention process to ensure effective dispersion in the aqueous-polymer solution.   
In the last section, an ultrasound sonifier was used for PEO-protein solution to prevent 
aggregation. The sonication works with the polymer-protein mixture to prevent 
aggregation because the main attraction from the protein macromolecular and nano-
particles would be the intermolecular force which includes van der Waal force and 
hydrogen bonding regarding the aqueous solution in use. Intermolecular force exists 
all the time but aggregation takes time as well. Therefore, if the ingredients disperse 
well in solution and this dispersion lasts until spinning, the aggregation can be 
prevented from forming composite nanofibres. However, due to the nature of magnetic 
nanoparticles in this study which gives a stronger and more immediate aggregation 
force, the ultrasound sonifier is no longer suitable for processing in the same way. To 
overcome the strong magnetic force of the particles, the citric acid coating of MNPs is 
introduced which covers MNP surface and raise mobility.   
Citric acid was dissolved in deionized water in a ratio of 0.5 g/l, at 90 °C for 1 hour, 
under magnetic stirring. Then, the stirrer was removed and a calculated weight of 
Fe3O4 MNPs was added to the solution and mixed for another 1 hour. Afterwards, the 
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acid coated MNPs were precipitated by placing a magnet under the bottom of the 
vessel, and the solution was decanted. The collected MNPs were then washed twice, 
with 100 ml of deionized water, and dried at 80 °C in the oven, for 3 hours or until a 
constant weight was obtained. Subsequently, the PVA solution was mixed with 
3%(wt), 4%(wt), 5%(wt) Fe3O4 magnetic nanopowder (~20 nm), coated with citric acid, 
and vigorously vortexed (VWR Analog Vortex Mixer) to obtain PVA-MNP solutions.  
3.2.4 Experimental set-up for fibre generation  
The experimental set-up of the infusion gyration process is shown in Figure 3-5. It 
consists of a rotary aluminium cylindrical vessel containing 20 small round orifices on 
the face (Figure 3-6).  
 
Figure 3-5 Infusion gyration set-up. (a) Syringe pump, (b) Syringe, (c) Solution tube, (d) Cylindrical vessel, (e) 
Speed controller and (f) Protection case. 
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The dimensions of vessel are 60 mm in diameter with a height of 50 mm. The orifices 
(20 in total) are 0.5 mm in diameter shared the same height of 25mm from the vessel 
bottom. One end of the vessel is joined to a syringe pump (PHD 4400 Programmable, 
Harvard Apparatus) through a rotary joint, which can control flow of the protein-
polymer mixture or control the polymer solution into the vessel.  
The bottom end of the vessel is connected to a DC motor, which can produce variable 
speeds up to 36,000 rpm (Figure 3-6). Because of the centrifugal force and the 
hydrostatic force, which overcome the surface tension force at the orifice, a jet is 
formed. The flow in the vessel is kept constant to minimize the hydrostatic force effect 
during gyration.  
 
Figure 3-6 Spinning system of infusion gyration. (a) Tube, (b) Connector, (c) Rotary joint, (d) Cylindrical vessel, 
(e) DC motor, (f) Crank and (g) Aluminium foil. 
A gradual increase of the rotating speed will elongate the formed jet when it comes 
out via the orifices and subsequently solvent evaporates occur to form solid micro and 
nano fibres. This unit is placed in a transparent plastic container to collect the polymer 
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fibres conveniently. The polymer fibres were collected using a stationary aluminium 
foil within the container. 
 
 
3.2.5 Fibre spinning 
3.2.5.1 PEO-protein 
In order to investigate the fibre size and size distribution under different conditions, 
three types of fluorescent protein(s) PEO combined solutions were spun at different 
flow rates (5000 µl/min, 4000 µl/min, 3000 µl/min, 2000 µl/min, 1000 µl/min and 500 
µl/min) under a constant rotating speed (36,000 rpm) at the ambient temperature 
(20±1 °C) and relative humidity (42±1%) (Table 3-2).  
Protein(s) type 
used 
Spinning solution composition Rotational 
speed 
DsRed_AuBP2 40g 10wt% 
PEO-water 
solution 
0.4ml DsRed_AuBP2 (with gold 
nanoparticles) 
36,000rpm 
GFPuv_AuBP2 40g 10wt% 
PEO-water 
solution 
0.4ml GFPuv_AuBP2 (with gold 
nanoparticles) 
36,000rpm 
MBP-DsRed-
AuBP2 & 
GFPuv_AuBP2 
80g 10wt% 
PEO-water 
solution 
0.8ml mixture made by 0.4ml 
GFPuv_AuBP2 (+ Au NPs) & 0.4 ml 
MBP-DsRed-AuBP2(+ Au NPs) 
36,000rpm 
Table 3-2 Parameters of fabrication (PEO-protein). 
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3.2.5.2 PVA-MNP 
All the pure PVA and PVA-MNP solutions, i.e. 0%(wt), 3%(wt), 4%(wt) and 5%(wt) 
MNPs in PVA aqueous solutions, were then spun into fibres, according to procedures 
described. During fabrication of the fibres, the rotational speed of infusion gyration was 
fixed at 36,000rpm for this study. The flow rate of the solution to the vessel was tried 
at 1000µl/min, 2000µl/min, 3000µl/min, 4000µl/min and 5000µl/min referring to the 
previous study. It was held at 4000µl/min during fabrication because it delivered the 
highest quantity of fibres. A stationary steel mesh was placed 120 mm away from the 
rotating vessel to help collect the fibres. The solutions were spun at the ambient 
conditions of 23±1 °C and 40±1% relative humidity (Table 3-3).  
Rotational 
speed 
Flow rate Mesh distance Ambient 
temperature 
Relative 
humidity 
36,000rpm 4000µl/min 120mm 23±1 °C 40±1% 
Table 3-3 Fabrication parameter of PVA and PVA-MNP solutions. 
After the spinning was completed, all samples were transferred to sealed containers 
for further characterization. 
 
 
3.2.6 Collection of fibres 
3.2.6.1 Natural organization 
At the early stage of using gyration, no specific tools were used for collection because 
a fibre sample can form a network itself around the motor and crank in the container. 
Careful transfer of the sample from the network to a glass slide or aluminium piece is 
Chapter 3 
83 
the only step needed. However, the sample cannot form a uniform shape and for some 
polymers, they do not grow nets. Many fibres are wasted while spinning because they 
stick on the protection paper or aluminium foil from the inner wall rather than attach to 
each other. This method is suitable for small scale trail of samples when the 
characterization does not require large amount (Figure 3-7).  
 
Figure 3-7 Natural organization of fibres. 
Two prototypes of the container were used for gyration. One is a sealed box with 
openable acrylic glass door to observe motor condition and fibre formation. It provides 
protection from solution spray but with less air flow for ventilation which is essential for 
fibre formation. In practice, a small gap (2-3 cm) is always left. Then, the other 
prototype has a sliding acrylic glass door which can be half open during spinning and 
covers the rotating part as protection. Sufficient air is for solution evaporation. 
However, strong solvent destroys acrylic glass which becomes less transparent and 
fragile after several times of use. PEO fibres were tried to collect using this method.  
Chapter 3 
84 
Therefore, some collectors were developed. The material is crucial as some solution 
with strong solvent can break the collector or corrode it causing the target sample to 
be disturbed. Metal is the priority choice regarding the requirement for most 
experiment.  
 
3.2.6.1 Collecting mesh 
To collect more fibres from each spinning, a stationary steel mesh was introduced 
placed 120mm away from the rotating vessel. One old version with each cell 75×15mm 
was used which gave a much better collection of fibres than natural organization but 
the small cell size caused inconvenience of getting fibres out.  
This situation happens on copper net collector as well which was used but later 
abandoned in laboratory due to difficult cleaning although the softness of copper 
makes it possible to form desired shapes for collection (Figure 3-8).  
Moreover, in order to catch more flying fibres around the spinning cylinder, a smaller 
cell is applied which also brings the inconvenience of fibre transfer.  
 
Figure 3-8 Copper net collector (a), (b) and (c) with cell size 25mm×25mm. 
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Therefore, a mesh with cell size 75×25mm is used for faster collection which speeds 
up the whole experiment process (Figure 3-9 a and b). After spinning, fibres on the mesh 
are easy to transfer. By this method, most of the fibres can be collected even to form 
a shape such as a mat, a ball or a sponge. It has been tested many times for collecting 
the magnetic PVA fibres which, afterwards, functions well for drug release test. (Figure 
3-9 c)  
 
Figure 3-9 Steel mesh (a) without and (b) with spinning cylinder. (c) PVA-MNP fibres collection. 
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3.3 Characterization Methods 
3.3.1 Solution properties  
As a review of the former chapter, the properties of the spinning solution need to be 
characterized either for electrospinning or gyration whose fibre forming process and 
outcome are influenced. The basic ones are quality controls for solution preparation 
so that the solutions can be ensured stable and under same conditions for each 
experiment.  
When the polymer requires temperature control during dissolving into solvent, a 
thermometer is used. The pH meter is for solutions requiring pH control such as PBS 
buffer.  
The physical or mechanical properties of the solution are also important because they 
are directly related to the performance of spinning. Through the measurement and 
comparison of the solution properties, the principle of polymer solution converting to 
fibres stands out. The surface tension and the viscosity of spinning solution are crucial 
in gyration fibre forming.  
To research the relationship between solution physical properties and the Berry 
number (a dimensionless index relates to fibre size), the measurements of surface 
tension and the viscosity for 5%(wt), 10%(wt), 15%(wt) and 21%(wt) PEO-water 
solutions were undertaken through a KRUSS K9 tensiometer (Figure 3-10 a) and a 
Brookfield DV-3 Ultra programmable rheometer (viscometer) (Figure 3-10 b), 
respectively, at ambient temperature (20±1°C). The meters are always calibrated 
before using.  
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Figure 3-10(a) KRUSS K9 tensiometer (b) Brookfield DV-3 Ultra programmable rheometer (viscometer).  
 
3.3.2 Environmental properties  
The environment is important for spinning and characterization. Humidity and ambient 
temperature are recorded by a humidity meter and a thermometer. These properties 
affects the formation of fibres because the evaporation is an indiscrete part during 
spinning. Moist fibres are difficult to collect. A sample desiccator is usually used if the 
fibre requires the drying process after collection.  
3.3.3 Optical microscopy 
Optical microscopy is for the morphology study of fibres generated such as shapes, 
size and diameter. PVA and PVA-MNP fibre samples were observed under a Nikon 
Eclipse ME 600 optical microscope, fitted with a Micropublisher 3.3 RTV, 3.3-
megapixel CCD Colour-Bayer Mosaic, Real Time Viewing camera (Media 
Cybernetics, Marlow, UK). These fibres were checked through an optical microscope 
with general larger scale rather than SEM because, for the following drug release test 
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demonstration, the shape of the fibres collected in its entirety exhibits more structure 
information for drug loading.  
3.3.4 Fluorescence microscopy 
A fluorescence microscope (EVOS FL Cell Imaging System, Life Technologies 
Limited) was used for detecting fluorescence along PEO-protein fibres. Images were 
taken both in transmitted light and red/green fluorescence for comparison. The fibres 
were characterized on the same position of the sample with fluorescence mode on 
and off to verify the integration of the peptides in the fibres. 
3.3.5 Scanning electron microscopy (SEM) 
The characteristics and the morphology of PEO-protein fibres with high magnification 
were studied using field emission scanning electron microscopy (Hitachi S-3400N 
Scanning Electron Microscope). The images were obtained with secondary electrons 
where the fibre samples were coated with gold using a sputtering machine (sputter 
time ~75s) before loading to the microscope.  
High and low magnification images were acquired at randomly selected positions 
(>20) within a sample. The fibre diameter was obtained using ImageJ software. About 
150 measurements per sample were made at random locations along the fibre to plot 
the fibre diameter distribution.  
The size and morphology of PVA and PVA-MNP fibres were analysed using field-
emission scanning electron microscopy (FESEM) with a JEOL JSM6310F instrument. 
All samples were coated with carbon prior to imaging, using a Quorum K975X turbo-
pumped thermal evaporator (Quorum Technologies Ltd., East Sussex, UK).  
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3.3.6 Energy-dispersive X-ray spectroscopy (EDX) 
EDX (Energy dispersive X-ray) spectroscopy which was used in this study of fibre 
research is a technique for chemical elemental analysis of specified sample area. EDX 
analysis was performed through an INCA X-sight EDAX system (Oxford Instruments) 
which was used with a Hitachi S-3400N. Surface elemental analysis with EDX 
spectrum and element dot mapping has been done on PVA-MNP fibres.  
 
3.3.7 High-speed camera 
To better understand the process of spinning, a high-speed camera system was used 
which can detect small changes in a very short time. Through high speed imaging of 
the rotating cylindrical vessel, the moment of the spinning solution coming out via the 
orifices can be captured which provides more detailed information of the production 
process. Spinning videos of infusion gyration were captured using FASTCAM SA1.1 
(PHOTRON, Bucks, United Kingdom) (Figure 3-11).  
 
Figure 3-11 High speed camera set up. (a)Laptop, (b)Camera, (c)Tripod, (d)Syringe pump, (e)Infusion gyration 
set up, (f)Light, (g)Light crank. 
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The lens used is TAMRON SP Di AF 90mm F/2.8 MACRO 55 272E which stays 0.5 
m to 1 m distance to the spinning cylinder depending on image and focus control while 
filming.  
By Photron FASTCAM Viewer (PFV) 3.6.7.0, the capturing software supplied by the 
high-speed camera company, the video can be played back at slow motion at a 
variable frame rate and saved by the cable connected laptop. 
 
3.3.8 UV-Vis spectroscopy  
The concentration of acetaminophen released into the solution through PVA-MNP 
fibres was measured via ultraviolet−visible spectroscopy (UV−vis) at a characteristic 
absorbance wavelength of 248 nm using the absorbance mode of a BioTek Synergy 
H1Multi-Detection Reader. These measurements were compared to a calibration 
curve, and the acetaminophen (model drug used in this study) concentrations of the 
experimental samples were determined by the Beer−Lambert law.  
Stability of the composite fibres (PVA-MNP) was also studied. Fibres were immersed 
in an absolute ethanol solution for 4 weeks to test Fe3O4 leaching via UV-Vis 
spectroscopy (Agilent Technologies Cary 4000 UV-Vis spectrophotometer).  
 
3.3.9 Fourier transform infrared spectroscopy (FTIR)  
Fourier transform infrared spectroscopy (FTIR) is used to detect the chemical 
composition of samples. The infrared spectra of PEO-protein fibres were recorded on 
Perkin Elmer Spectrum-400 FTIR spectrometer between 4000 cm-1 and 650 cm-1 with 
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a resolution of 4 cm-1. To obtain a reasonable signal-to-noise ratio, the average of 20 
scans was taken. Samples were analysed directly by single-bounce diamond ATR.  
The chemical composition of the PVA-MNP fibre sample was analysed using FTIR. 
This characterization was achieved via FTIR spectroscopy, with a Bruker Vertex 70 
instrument. Examination of the FTIR peaks allowed the identification of all the typical 
peaks for PVA and citric acid.  
 
3.3.10 SQUID analysis 
In order to correctly quantify the amount of MNPs loaded on to fibres, the material was 
subject to superconducting quantum interference device (SQUID) analysis. 
Magnetization measurements were performed using a Quantum Design MPMS 
SQUID-VSM magnetometer. Samples were weighed and mounted within 
polycarbonate holders and subsequently measured (±1 T, 796 kAm-1, at 300 K).  
 
3.3.11 Copper binding assay  
Significant quenching of the red fluorescence activity occurred from studies in the 
presence of copper ions. Thus, the potential of using the fibres for rapid monitoring for 
the presence of copper ions has been explored, a major component in heavy metal 
pollution.  
To understand the quenching mechanism of fibre, the metal ion binding study was 
carried out against copper ions. Different concentrations of copper solution were 
added to fibre samples in 100 μL of 3-(N-morpholino)propanesulfonic acid buffer. The 
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fluorescence intensity was measured (Varian Cary Eclipse Fluorescence Reader) by 
recording the resulting emission at 590 nm wavelength after the excitation of the 
samples at 558 nm wavelength.  
3.3.12 Localized surface plasmon resonance spectroscopy (LSPR)  
The effect of proteins on the plasmon excitation wavelength for gold nanoparticles (Au 
NPs) was analysed by measuring the light absorbance of Au NPs in the absence and 
the presence of protein-conjugated Au NPs in the fibre using a Cytation 3 Imaging 
Multi-Mode Plate Reader (BioTek Instruments, Inc., Vermont, USA). Each spectrum is 
an average of three individual samples recorded twice. Herein, LSPR bio-sensing 
measurement was based on the resonant interaction induced by the biomolecules 
binding onto the nanoparticle surface. The change in the local dielectric owing to 
molecule recognition and binding was measured by a shift in the LSPR λmax.  
3.4 Controlled Drug Release Experiment  
Drug release experiments were conducted in absolute ethanol medium, with 
acetaminophen (Sigma Aldrich, analytical standard) chosen as a model drug for this 
study due to its high solubility in ethanol131 and its characteristic UV-Vis absorption132. 
For each experiment, 5.0 mg of acetaminophen powder was weighted and transferred 
on to 60.0 mg of magnetic fibres prepared. The fibres were wetted with three drops of 
absolute ethanol, prior to transfer of acetaminophen on to them (Figure 3-12). To ensure 
that the drug was effectively immobilized in the fibre network, the acetaminophen 
powder was spread throughout and pressed against the fibres with a spatula.  
This system was then transferred to a glass vial containing 10.0 ml of absolute ethanol. 
Both control experiments and actuation experiments were conducted in duplicate, to 
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measure the release of acetaminophen into the solution with time. For the actuation 
experiments, the fibre-drug system was continuously moved via four stacked external 
neodymium magnets (emagnets UK, EP336, 20 mm dia x 5 mm - N42 - NiCuNi plated 
– 1.4 T) (Figure 3-12 C). Samples of 500 µl of the ethanol solute were taken out from 
the system, first after every minute, up to 5 minutes, and then, at every 5 minutes, for 
a total period of 30 minutes. Subsequently, the samples were analysed via UV-Vis 
spectrophotometry, to determine the concentration of acetaminophen released via 
magnetic actuation. The 500 µl taken out for sampling was replaced with new ethanol 
each time, in order to keep a total constant volume of 10 ml of ethanol throughout the 
experiment. The same procedure was followed to conduct control experiments, with 
the exception of the magnetic actuation.   
 
Figure 3-12 Drug release experiments using magnetic fibres. (A) Loading of acetaminophen onto the fibres, (B) 
control experiment without any actuation, (C) fibre-drug system actuated via an external magnet.   
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Chapter 4.  
Fabrication of PEO fibres with fluorescence protein using infusion gyration   
4.1 Introduction   
The infusion gyration method resulting in the formation of bio-hybrid fibres containing 
the genetically engineered protein and gold nanoparticles (AuNPs) was developed.  
(1) Gold nanoparticles (AuNPs) were functionalized with DsRed-AuBP2 in which the 
DsRed protein was fused with gold binding peptide. (2) Polyethylene oxide (PEO) 
polymer solution was mixed with DsRed_AuBP protein functionalized AuNPs. (3) 
Through the infusion gyration method, bio-hybrid fibre was produced which is 
embedded with functional protein and nanoparticles as depicted in Figure 4-1.  
 
Figure 4-1 Schematic illustration of the formation of engineered fluorescent protein (DsRed) integrated fibres.  
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GFP_AuBP2 was used for green fluorescence, and a mixture of red and green 
fluorescence proteins was tried to test the compatibility of the fibre system.    
 
4.2 Berry Number  
In fibre forming processes, the physical properties of polymer solution (viscosity and 
concentration) influence the resulting fibre size and fibre morphology3,5. It has been 
shown that the fibre size obeys a power law relationship relative to the viscosity and 
the concentration of the polymer solutions134.  
d = ηa  --------- (1) 
d = Cb  --------- (2) 
Where d is the fibre size, η is the viscosity, C is the concentration, a and b represent 
constants (experimental). 
Combining equations (1) and (2) will result in the power law relationship that is, 
η = Cc  ---------(3) 
Where c is the scaling exponent. 
In a typical pressurised gyration process not only the viscosity and polymer 
concentration influences the fibre size but also the polymer chain entanglement, which 
is a prerequisite to form the nanofibres5. To verify this in the infusion gyration process 
an analysis procedure was adopted using the Berry number, which is a dimensionless 
index used to control and indicate the fibre size in fibre processing methods. 
Be = [η]C  -------- (4) 
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In equation (4) above, Be is the Berry number, [η] is the intrinsic viscosity and C is the 
concentration.  
Table 4-1 shows the solution physical properties and the Berry number obtained for 
various concentrations of PEO (in water) polymer solution.  
Polymer concentration 
(wt%) 
Viscosity 
(mPa s) 
Surface tension 
(mN/m) 
Berry number 
(Be) 
 
5 
 
75±4 
 
50±1 
 
1.6 
10 390±23 51±1 3.2 
15 2200±75 52±2 4.8 
21 3000±86 57±2 6.72 
Table 4-1 Polymer concentration, viscosity and Berry number for PEO solutions at ambient temperature 
(20±1°C).  
To derive the Berry number, the intrinsic viscosity of the PEO is taken as 0.32 dl/g 
(measured and calculated in laboratory). Figure 4-2 (a) shows the relationship 
between the polymer concentration and the viscosity of the PEO-water solution.  
 
Figure 4-2 Relationship between (a) the viscosity and polymer concentration and (b) the Berry number and 
structures (36,000rpm). 
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It is clearly seen that when the concentration is low the viscosity is also low. When the 
concentration increases the viscosity increases gradually until a specific value is 
reached, after which the viscosity increases considerably. The non-linear behaviour is 
attributed to the relationship between the polymer concentration and the viscosity and 
for the PEO-water solutions equation (3) above gives η=0.92C2.73 (determined from 
Figure 4-2 (a) ).  
For linear polymers in a good solvent, η ~ C1.0 in the dilute regime, η ~ C1.25 in the 
semidilute unentangled regime, η ~ C4.8 in the semidilute entangled regime, and η ~ 
C3.6 in the concentrated regime.27 The scaling dependence for PEO solutions is much 
lower than that for linear poly(ethylene terephthalate co-ethylene isophthalate) and 
similar to branched poly(ethylene terephthalate co-ethylene isophthalate) in 
chloroform/dimethylformamide where η ~ C6.0 and η ~ C2.73 , respectively135. In addition, 
it is closer to the value, η ~ C3.28, reported for Gelose 80 starch in the semidilute 
entangled regime136. In the semidilute, unentangled region, the polymer chains overlap 
each other, but does not form entanglement. In the semi-dilute entangled region 
polymer chains sufficiently overlap each other and form entanglement, resulting in a 
network structure.  
The linear polymer has extended coils and form strong entanglements whereas the 
branched polymer forms weaker entanglements3. Figure 4-2 (b) shows the relationship 
between the Berry number and structures formed in the process under the condition 
of 36,000rpm (maximum stable rotating speed due to the motor performance). In dilute 
polymer solutions, Be < 1.6, fibres could not be formed due to insufficient polymer 
chain entanglement. When the 1.6 < Be < 3.2 the fibres formed only at a rotating speed 
of 36,000 rpm. This is due to the increase of the time constant of forces acting on the 
polymer solution and a more viscous response of the polymer solution. Thus, it 
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requires a minimum rotating speed of 36,000 rpm to initiate the fibres5. When the 3.2 
< Be < 4.8 there is sufficient amount of chain overlap and entanglement to form the 
fibres. However, when the Be > 4.8 much thicker fibres are obtained. Therefore, a 10wt% 
PEO polymer solution was selected for integration of Ds-Red-AuBP2 protein in the 
fibres.  
 
4.3 Fibre Yield  
Fibre yields at the six different flow rates with same polymer solution of 10wt% PEO-
water are shown in Table 4-2. The yield is calculated from both the flow rate (which 
gives the mass transfer per unit time) as well as the weight of the final products.   
Infusion rate (µl/min) 5000 4000 3000 2000 1000 500 
Weight of polymer solution (g) 6.20 6.17 6.16 4.95 6.55 7.13 
Weight of PEO (g) 0.620 0.617 0.616 0.495 0.655 0.713 
Weight of PEO (mg) 620 617 615 495 655 713 
Weight of fibres collected (mg) 27.3 19.7 5.5 3.0 3.9 3.7 
Input-output ratio (%) 4.4 3.2 0.9 0.6 0.6 0.5 
Yield (g/hr) 1.45 0.86 0.18 0.08 0.04 0.02 
Table 4-2 Yield of peptide integrated fibres at various infusion rates (10wt% PEO-water solution). 
Moreover, the yield is plotted (Figure 4-3). It is clearly seen that the yield nearly doubles 
with doubling the flow rate until the value of 3000μl/min was reached, after which, the 
yield increased dramatically when compared to the lower flow rate yields. The yield 
obtained for the infusion gyration method was lower than that achieved through 
traditional pressurised gyration. This may be due to the absence of blowing in the 
former5. However, rather than the run-to-stop process of pressurised gyration which 
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spins in a very short time after solution adding, infusion gyration provides a more stable 
output through flow rate control which also restricts fibre yield due to controlled mass 
delivery.  
 
Figure 4-3 Infusion rate effect on fibre yield. 
When collecting the fibres from the spinning container, there is always a loss because 
some fibres may strongly attach to the collector or form in the places where to pick 
with difficulties such as corners as well as working parts with an irregular surface. 
Furthermore, some spray drops were observed which means part of the solution did 
not spin into fibres. However, these fibres were collected strictly following the same 
procedure which reveals the actual relationship between each other for production and 
collection in manufacturing process.  
As the flow rate controls the yield (which controls the mass output per unit time), for 
the results, linear change is divided into two phases which are from 500μl/min to 
2000μl/min and from 3000μl/min to 5000μl/min. The ideal change should be always 
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linear, for example, with flow rate increasing from 2000μl/min to 4000μl/min which 
doubles the former, the yield should also double. Because as flow rate doubles, the 
volume of solution doubles in unit time which means doubled mass is spun. However, 
the real yield of 2000μl/min is far too low compared to the one expected. A conclusion 
can be made that, for lower flow rate, the converting efficiency of solution into fibres is 
lower. Here, the concept of input-output ratio for fibre spinning is introduced which 
represents the solution-fibre transform efficiency of the system (Figure 4-4).  
 
Figure 4-4 Infusion rate effect on Input-output ratio. 
It is seen that at lower flow rates, the ratio is extremely low. Therefore, by following the 
principle of yield performance, either high flow rate is adopted for large scale 
manufacturing, or low flow rate can be applied for a combined production of fibres with 
other products like spay particles, in the future.   
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 1000 2000 3000 4000 5000 6000
In
p
u
t-
o
u
tp
u
t 
ra
ti
o
 (
%
)
Infusion rate (μl/min)
Chapter 4 
101 
4.4 Addition of DsRed-AuBP2 to 10wt% PEO-water solution 
4.4.1 Self-assembly of DsRed_AuBP2 on Au substrate  
To assemble the fusion protein onto a gold surface, a gold surface was generated 
using micro-contact printing (μCP), onto where the proteins were directly applied. An 
AFM image (Figure 4-5) was recorded in tapping mode with a silicon cantilever at a 1 
Hz scan rate and shows that DsRed-AuBP2 strongly binds exclusively to the gold 
region of the patterned surface. The AuBP2 peptide tag was confirmed to provide self-
immobilization on the gold surface with consequential direction for the engineered 
fluorescence protein to self-assemble and develop a protein-based pattern. 
 
 
Figure 4-5 Schematic representation of (a) the generation of two-dimensional arrays of immobilized proteins on 
a patterned substrate fabricated through μCP and (b) fluorescence microscopy (FM) image of gold substrate 
following self-assembly of DsRed-AuBP2. (c) AFM image of gold substrate following self-assembly of DsRed-
AuBP2 with height profile of the arrays.133  
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4.4.2 Fibre morphology 
The gold nanoparticles attachment to the fibres are verified through SEM (with focused 
ion beam) using a dual beam (Helios) machine. The fibrous sample is cut through a 
section using low beam current (40 pA) and the dispersion of nanoparticles on the 
surface (indicated by arrows) was observed (Figure 4-6).  
 
Figure 4-6 Focused ion beam SEM images. 
Figure 4-7 - Figure 4-12 provide details regarding the fibre size (diameter) and size 
distribution of the protein-integrated fibres produced. These ranged from 117 to 216nm 
in average diameter for the six different flow rates studied. At the lowest flow rate, 
500µl/min, the mean fibre size diameter was 117nm. When the flow rate was doubled 
to 1000µl/min the mean fibre size was 161nm. Surprisingly, the flow rate of 3000μl/min 
resulted in a reduced mean fibre size of 132nm and this is explained below. The initial 
size increasing trend continued at higher flow rates, however, at 4000μl/min size was 
190nm, and at 5000µl/min 216nm.  
The polydispersities of the fibre size distributions were 47, 32, 19, 26, 25, & 23% for 
flow rate values of 500, 1000, 2000, 3000, 4000, and 5000μl/min, respectively, with 
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the rotating speed remaining constant at 36,000 rpm. The morphology of fibres 
revealed continuous, uniform structures. Single strand pore-free fibres were bundled 
together and it was also possible to form well-aligned structures due to the high 
stretching force experienced during gyration. Compared to pressurised gyration, the 
ability to use higher flow rates allows increased hydrostatic pressure which was kept 
constant for flow rates at a fixed rotating speed by ensuring continuous flow. However, 
the hydrostatic pressure is much lower than the centrifugal force at the orifice.  
 
Figure 4-7 Fibre diameter distribution and the corresponding SEM image of fibres at 500 µl/min. 
 
Figure 4-8 Fibre diameter distribution and the corresponding SEM image of fibres at 1000 µl/min. 
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Figure 4-9 Fibre diameter distribution and the corresponding SEM image of fibres at 2000 µl/min. 
 
Figure 4-10 Fibre diameter distribution and the corresponding SEM image of fibres at 3000 µl/min. 
 
Figure 4-11 Fibre diameter distribution and the corresponding SEM image of fibres at 4000 µl/min. 
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Figure 4-12 Fibre diameter distribution and the corresponding SEM image of fibres at 5000 µl/min. 
This allows the destabilizing centrifugal force and the withholding surface tension force 
to determine the final size and size distribution of the fibres. Moreover, the flow rate 
regulates the volume of material and the mass transfer across the orifice. Then the 
relationship between the infusion flow rate and the fibre mean diameter can be drawn 
in Figure 4-13.  
 
Figure 4-13 Infusion flow rate effect on the fibre mean diameter. DsRed-AuBP2.  
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The overall increase of fibre diameter with increasing flow rate is attributed to this 
phenomenon. The drop in fibre diameter observed at 3000μl/min, and subsequent 
increase at higher flow rates may be attributed to the balance of solvent evaporation 
and change in the volume of material at the orifice. At lower flow rates, the solvent has 
enough time to evaporate, allowing the polymer jet more time to stretch which results 
in the formation of finer fibres. At higher flow rates, the solvent does not have sufficient 
time to evaporate before reaching collection. Therefore, a coarser fibre is formed137,138. 
Additionally, in infusion gyration the volume and shape of the polymer droplets vary 
for different flow rates at the orifice which could cause differences in fibre size and size 
distribution. Finally, during spinning, the travelling polymer jet experiences 
aerodynamic forces that may impact the stretching of the jet and, thereby further alter 
the final size and size distribution.  
4.4.3 Fluorescence microscopy  
The fluorescence contrast image shows the attachment of protein-AuNP mixture 
dispersed in the fibres (Figure 4-14).  
 
Figure 4-14 Ds-Red-AuBP2 proteins attached to the fibres fluorescence contrast images. 
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Moreover, the fluorescence microscopy images obtained for various conditions are 
shown in Figure 4-15 - Figure 4-20. The pictures on the left show the optical images 
whereas those on the right display the corresponding fluorescence images for various 
flow rates.  
In each instance red fluorescence is a document to reveal a smooth structure. These 
images indicate the excellent integration of engineered protein with gold binding 
peptides in the fibres and the flow rate variation does not violate their performance on 
this level. The excellent alignment of the peptide integrated fibres may be due to 
tension experienced by fibres and the interaction of the gold binding peptides to the 
surface of the fibres which aid to prevent slippage of the bonds that may otherwise 
arise from shearing action.  
It is also suggested that the method could be utilized to make various structures that 
could be tuned physically or chemically without significant variation along the fibrous 
structures.  
 
 
Figure 4-15 Fluorescence microscopy images of the products at 500 µl/min. 
Chapter 4 
108 
 
Figure 4-16 Fluorescence microscopy images of the products at 1000 µl/min. 
 
Figure 4-17 Fluorescence microscopy images of the products at 2000 µl/min. 
 
Figure 4-18 Fluorescence microscopy images of the products at 3000 µl/min. 
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Figure 4-19 Fluorescence microscopy images of the products at 4000 µl/min. 
 
Figure 4-20 Fluorescence microscopy images of the products at 5000 µl/min. 
Additionally, bio-hybrid mats composed of micro and nano fibres were analysed in 
both dry and wet conditions using a cell imaging multi-mode reader and indicate that 
protein-integrated samples did not dissolve in aqueous environments and that similar 
fluorescent images were obtained in both dry and wet forms (Figure 4-21). Thus, protein-
based fibres did not show any leakage of protein into the PBS buffer which was verified 
through fluorescence analysis of the buffer solution after the fibres were removed. 
Interestingly, as expected, PEO fibres that were not integrated with proteins dissolved 
completely when exposed to an aqueous environment, suggesting a stabilizing role of 
the protein nanoassemblies on the fibres. Here, engineered DsRed-AuBP2 proteins 
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were utilized due to their low autofluorescent potential given their excitation and 
emission wavelengths in the near far-red region of the spectrum which allow for a 
higher signal to noise ratio.  
 
Figure 4-21 Fluorescence Microscope image of protein integrated fibres (a-b) samples were in PBS buffer, (c-d) 
samples in dry condition.  
 
 
4.4.4 FTIR  
FTIR (Fourier transform infrared spectroscopy) analysis conducted on the PEO and 
bio-hybrid (PEO/Protein) fibres confirmed the presence of the protein. Figure 4-22 
depicts the characteristic peaks of PEO are observed at 2900 cm-1 (methylene group 
CH2 molecular stretching), and at 1100 cm-1 and 960 cm-1 (C-O-C group stretching), 
139–141. A change in bandwidth for the absorption centred around 2880 cm-1 also 
occurred and changed further with protein integration.   
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Figure 4-22 FTIR spectra of the samples. X-axis is wavenumber (cm-1).   
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Engineered proteins in the PEO/Protein fibres resulted in an FTIR peak at 1720 cm-1, 
representing the characteristic amide bonds of protein. After washing the PEO/Protein 
fibres with PBS, the same FTIR peak was still observed. The maintained carbonyl 
peak suggests that the protein remained bound to the surface of the AuNPs which 
were integrated in the PEO fibres, even following a washing step. This is remarkable 
protection of the water soluble PEO polymer and is discussed further below.  
Integrating discrete AuNPs into the hybrid fibres may significantly alter their inherent 
optical properties which were evaluated by UV-Vis and fluorescence 
spectrophotometry. The integration of AuNPs onto the surface of the fibres had a 
significant effect which was observed, when compared to non-protein integrated fibres. 
Hybrid fibres in PBS buffer exhibited a strong fluorescence emission band at 
wavelength 570nm (Figure 4-23). Interestingly, protein based fibres did not dissolve in 
PBS buffer and did not show any leakage of protein to the buffer. When fibres were 
removed from the PBS buffer, the fluorescence intensity of PBS buffer alone was 
completely mitigated confirming that the red fluorescent protein did not leak into PBS 
buffer (Figure 4-24). 
 
Figure 4-23 Optical characteristics of PEO and PEO/Protein fibres measured by fluorescence spectrophotometry. 
Fibres containing red fluorescence protein in PBS buffer.  
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Figure 4-24 Optical characteristics of PEO and PEO/Protein fibres measured by fluorescence spectrophotometry. 
The removal of the PEO/Protein fibres from PBS buffer diminishes fluorescence intensity demonstrating no 
significant protein leakage into the solution.  
 
4.4.5 Copper binding assay  
The PEO-protein fibres were investigated if they would demonstrate the selective 
binding to copper ion once they are placed in solution having copper ion. Based upon 
the fluorescence intensity plotted against the wavelength, the fibres were 
demonstrated quenching around 70% through 50μM copper concentration (Figure 4-25).  
 
Figure 4-25 Titration of DsRed-AuBP2 integrated fibre with Cu2+. Emission spectra was obtained by excitation at 
558 nm in the presence of 10, 20, 50μM Cu2+.  
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With the increasing amount of copper ion, the fluorescence intensity decreases which 
means part of the protein in the fibre binds the copper ion and lose fluorescence. This 
promising result not only demonstrates the potential of protein-integrated fibres to 
monitor the presence of copper ions in solution, but also establishes the potential 
environmental impact that may be achieved through further tuning of the system to 
detect biological and chemical changes in the environment.  
The results provide evidence that the red-fluorescence activity of the engineered 
proteins embedded in the fibres maintain full functionally and can respond to various 
dynamic conditions.   
 
4.5 Addition of GFPuv-AuBP2 to 10wt% PEO-water solution 
4.5.1 Fluorescence microscopy  
Figure 4-26 - Figure 4-31 display the fluorescence microscopy images of the fibre samples 
in experiment sequence from low flow rate (500μl/min) to high flow rate (5000μl/min).  
Every fibre sample with different infusion flow rate was photographed at the same 
position of fibres in transmitted light mode and in fluorescence mode for comparison.  
Two levels of scale were recorded during observation.  
For both 100μm scale and 1000μm scale images, individual fibre grows straight and 
smoothly through transmitted light for all different flow rates.  
In fluorescence mode, all images confirm the fluorescence along fibres at both scales 
which display the red colour (the red only indicates the fluorescence not represents 
the actual colour of the protein) in dark field. At these scales, there is no detectable 
difference by morphology between the six fibre samples of different flow rate.  
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Figure 4-26 Fluorescence microscopy of GFPuv-AuBP2 PEO fibres (500μl/min).  
 
Figure 4-27 Fluorescence microscopy of GFPuv-AuBP2 PEO fibres (1000μl/min). 
Chapter 4 
116 
 
Figure 4-28 Fluorescence microscopy of GFPuv-AuBP2 PEO fibres (2000μl/min). 
 
Figure 4-29 Fluorescence microscopy of GFPuv-AuBP2 PEO fibres (3000μl/min). 
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Figure 4-30 Fluorescence microscopy of GFPuv-AuBP2 PEO fibres (4000μl/min). 
 
Figure 4-31 Fluorescence microscopy of GFPuv-AuBP2 PEO fibres (5000μl/min). 
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The effect of infusion flow rate on fibre shape is hard to be observed from the 
fluorescence images due to low magnification. However, this will be discussed in the 
next section where SEM is used at nanometre level with higher observation capacity. 
The protein is well-distributed in the fibres because all fibres show uniform 
fluorescence compared to the same positions observed through transmitted light. 
Compared to the results of previous addition, similar fluorescence outcome confirms 
the integration of engineered protein with gold nanoparticles to the polymer fibres.  
The function of fluorescence protein works well after the fibre produced using this 
method. The 1000μm scale images show brighter colour due to more focus in a small 
field giving stronger fluorescence to the sensor of the microscope which submits better 
results of protein presence and distribution in fibres.  
4.5.2 Fibre morphology  
Figure 4-32 - Figure 4-37 show the SEM images along with the fibre diameter distributions. 
Images were recorded for each fibre sample produced at a flow rate of 500μl/min, 
1000μl/min, 2000μl/min, 3000μl/min, 4000μl/min or 5000μl/min. Measurement was 
taken for the calculation of the average fibre diameter as well as size distribution. 
 
Figure 4-32 Size distribution of GFPuv-AuBP2 PEO fibres (500μl/min). 
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Figure 4-33 Size distribution of GFPuv-AuBP2 PEO fibres (1000μl/min). 
 
Figure 4-34 Size distribution of GFPuv-AuBP2 PEO fibres (2000μl/min). 
 
Figure 4-35 Size distribution of GFPuv-AuBP2 PEO fibres (3000μl/min). 
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Figure 4-36 Size distribution of GFPuv-AuBP2 PEO fibres (4000μl/min). 
 
Figure 4-37 Size distribution of GFPuv-AuBP2 PEO fibres (5000μl/min). 
The fibres display smooth shape without beads at this level. The plotted graph shows 
a trend of diameter increasing as flow rate grows (Figure 4-38).  
The mean value of fibre diameter increases from 119nm to 185nm as the flow rate 
goes up from 500μl/min to 5000μl/min. However, from 2000μl/min to 4000μl/min, the 
curve is quite flat and the point at 3000μl/min decreases a little bit in the trend which 
also appeared in previous addition with DsRed-AuBP2 even at the exact 3000μl/min. 
The possible reason has been proposed in the last section (addition of DsRed-AuBP2) 
where the same idea may be shared. 
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Figure 4-38 Infusion flow rate effect on the fibre mean diameter. GFPuv-AuBP2.  
At or around this point, the balance may occur between the solvent evaporation and 
the volume of material change at orifice. The source of this balance needs to be 
analysed and will be discussed in Chapter 6. This phenomenon is confirmed because 
it happens in two additions with the same process conditions (flow rate, gyration speed 
and etc.) but different mixture materials (one is DsRed-AuBP2 and another is GFPuv-
AuBP2). A repeat study will be in the next section. Moreover, this trend information is 
useful on flow rate selection for spinning in the future. 
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4.6 Addition of GFPuv-AuBP2 & MBP-DsRed-AuBP2 to 10wt% PEO-water 
solution 
4.6.1 Fluorescence microscopy  
Table 4-3 - Table 4-8 show the compared fluorescence microscopy images of fibre with 
two mixed proteins following an increasing flow rate with the same order as the past 
two additions from 500μl/min to 5000μl/min. Every fibre sample with different infusion 
flow rate was photographed at the same position of fibres in transmitted light mode, 
green fluorescence mode and red fluorescence mode for comparison.  Two levels of 
scale (100μm and 400μm) were recorded during observation.  
Similar to the previous addition of GFPuv-AuBP2, the fibres of all batches show 
continuous and uniform structure on apparent morphology through transmitted light 
with undetectable difference on shapes between each other at these scales.  
Moreover, both green fluorescence images and red fluorescence images for the same 
batch support the present evidence as well as the working status of GFPuv-AuBP2 
and MBP-DsRed-AuBP2 proteins in fibre because of the positive fluorescence sign 
shown in both pictures. It also confirms that these two proteins function well with no 
disturbance on each other when they are mixed together at the same volume in PEO-
water solution.  
They did not lose their respective fluorescence after being processed into fibres. This 
means these two proteins can be used together as composite materials for fibre which 
will enhance its complexity and flexibility. The same volume mixture of the proteins is 
noticed in this addition. The ratio of protein mixture may deliver a different level of red 
or green fluorescence for presenting fibres with designed proportion of light intensity 
on different wavelengths in some application.   
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MBP-DsRed-AuBP2 & GFPuv-AuBP2 Mixture-PEO fibres (500μl/min) 
Transmitted light image Red fluorescence image Green fluorescence image 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-3 Fluorescence microscopy images of mixed protein PEO fibres at a flow rate of (a) 500μl/min. 
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MBP-DsRed-AuBP2 & GFPuv-AuBP2 Mixture-PEO fibres (1000μl/min) 
Transmitted light image Red fluorescence image Green fluorescence image 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-4 Fluorescence microscopy images of mixed protein PEO fibres at a flow rate of (b) 1000μl/min. 
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MBP-DsRed-AuBP2 & GFPuv-AuBP2 Mixture-PEO fibres (2000μl/min) 
Transmitted light image Red fluorescence image Green fluorescence image 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-5 Fluorescence microscopy images of mixed protein PEO fibres at a flow rate of (c) 2000μl/min. 
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MBP-DsRed-AuBP2 & GFPuv-AuBP2 Mixture-PEO fibres (3000μl/min) 
Transmitted light image Red fluorescence image Green fluorescence image 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-6 Fluorescence microscopy images of mixed protein PEO fibres at a flow rate of (d) 3000μl/min. 
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MBP-DsRed-AuBP2 & GFPuv-AuBP2 Mixture-PEO fibres (4000μl/min) 
Transmitted light image Red fluorescence image Green fluorescence image 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-7 Fluorescence microscopy images of mixed protein PEO fibres at a flow rate of (e) 4000μl/min. 
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MBP-DsRed-AuBP2 & GFPuv-AuBP2 Mixture-PEO fibres (5000μl/min) 
Transmitted light image Red fluorescence image Green fluorescence image 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-8 Fluorescence microscopy images of mixed protein PEO fibres at a flow rate of (f) 5000μl/min.   
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4.6.1 Fibre morphology  
Figure 4-39 - Figure 4-44 give the SEM images of fibre samples with different infusion flow 
rate by the same value and order of the previous addition (GFPuv-AuBP2). The 
average diameter of the fibres was measured and recorded for the size distribution 
calculation. The fibres are still smooth and uniform. The mean values of the fibre 
diameter show a decreasing trend (138nm, 125nm, 137nm, 133nm, 124nm and 
117nm) as the flow rate increases (500μl/min, 1000μl/min, 2000μl/min, 3000μl/min, 
4000μl/min and 5000μl/min) except the one of 1000μl/min (125nm).  
 
Figure 4-39 Size distribution of GFPuv-AuBP2 mixed with MBP-DsRed-AuBP2 PEO fibres (500μl/min). 
 
Figure 4-40 Size distribution of GFPuv-AuBP2 mixed with MBP-DsRed-AuBP2 PEO fibres (1000μl/min). 
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Figure 4-41 Size distribution of GFPuv-AuBP2 mixed with MBP-DsRed-AuBP2 PEO fibres (2000μl/min). 
 
Figure 4-42 Size distribution of GFPuv-AuBP2 mixed with MBP-DsRed-AuBP2 PEO fibres (3000μl/min). 
 
Figure 4-43 Size distribution of GFPuv-AuBP2 mixed with MBP-DsRed-AuBP2 PEO fibres (4000μl/min). 
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Figure 4-44 Size distribution of GFPuv-AuBP2 mixed with MBP-DsRed-AuBP2 PEO fibres (5000μl/min). 
From plotted Figure 4-45, it is seen that there are two differences for this part compared 
to the previous additions. One is the trend on mean diameter of this addition which 
has an opposite direction to both previous ones with the same increasing fibre size in 
general. Another is the flow rate ‘dropping point’ (1000μl/min), which has been 
discussed in the last section, of this addition which differs from the other two which 
share the same point of 3000μl/min.  
 
Figure 4-45 Infusion flow rate effect on the fibre mean diameter. Mixed proteins.  
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The concentration of the solutions and the gyration conditions for all three additions 
are the same. However, this one has two types of protein mixed in the polymer solution 
which clearly affects the process of fibre forming. The mixture may change the 
property of the solution and shift the trend. The phenomenon of a lower point in 
between the values still exists in this addition. Therefore, in this fibre process system, 
the ‘dropping point’ regarding the particular flow rate always exists in general which 
can be influenced by the solution property. This needs to be taken into consideration 
when a desired fibre size is decided to achieve through controlling the flow rate during 
the experiment. The discussion will be made depending on the results from all 
additions.  
 
4.7 Effect of Flow Rate  
From all three types of fibre formation outcome, the data can be combined illustrating 
the effect of flow rate on the fibre size (Figure 4-46).  
 
Figure 4-46 Infusion flow rate effect on the fibre mean diameter. 
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Firstly, the change for all samples on fibre size is not large (50nm – 280nm) which 
promise the applications requiring size control on this level. Then, the size of three 
samples is observed very close on 3000μl/min which makes this point ‘strange’. The 
huge drop for DsRed sample happens at this flow rate point which was also recorded 
for pressure coupled infusion gyration (see Chapter 2). It is noted that pressure 
coupled infusion gyration uses different concentration of PEO-water (5%, 10%, 15% 
and 21% in weight) for comparison, however, the variety of pressure and rotating 
speed shows no influence on this ‘strange point’ which means this point only relates 
to flow rate. As the point comes along with the infusion flow rate factor, this interesting 
phenomenon has not been reported in other methods such as pressurised gyration 
which will be fully discussed in Chapter 6 delivering possible explanation.  
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Chapter 5.  
Fabrication of PVA fibres with magnetic nanoparticles for remote-controlled 
drug release   
5.1 Introduction  
The goal of this study is to demonstrate a magnetically actuated drug delivery system, 
based on PVA-MNP fibres, generated via infusion gyration (Figure 5-1). The fibres are 
made of biocompatible components targeting biomedical applications, specifically, 
drug release. The ability of these fibres to be actuated via an external magnetic field 
is demonstrated, along with extensive characterization of its physical-chemical 
properties. The release of controlled quantities of acetaminophen, via magnetic 
actuation of this material, is explored. Furthermore, the advantages and potential 
scope of application, beyond drug-delivery, are discussed.  
 
Figure 5-1 Fabrication of PVA fibres with magnetic nanoparticles. 
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5.2 High Speed Camera 
Figure 5-2 shows the snapshot images of the video which records the fibre formation 
of PVA aqueous solution around the spinning cylinder. Moreover, Figure 5-3 indicates 
the moment of the polymer solution jet coming out of the vessel orifice. From these 
images, it is known that infusion gyration is functioning well and stable. 
 
Figure 5-2 High-speed camera snapshot images of the spinning cylinder showing fibre formation during the 
infusion gyration process. The red arrow indicates the solution jet (a)(b)(c). 
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Figure 5-3 High-speed camera snapshot images of the spinning cylinder showing fibre formation during the 
infusion gyration process. The red arrow indicates the solution jet and the yellow square indicates jet dragging 
(a)(b). 
The drag of the polymer solution jet which is included in the fibre formation process 
theoretically is confirmed by practice.  
5.3 SEM and Fibre Morphology 
Four different solutions were made and spun for study which are pure PVA solution 
(0%), 3%(wt), 4%(wt) and 5%(wt) of MNPs under the same conditions of 36,000rpm 
and flow rate 4000µl/min. In the practice of solution mixture making, 5 % (wt) MNPs in 
PVA solution is close to the limit of mixing. Beyond 5 % (wt), the solution reaches a 
‘saturation’ status which starts having MNPs in the bottom of the bottle as precipitate. 
To research the MNP concentration effect on the final fibre product, four samples were 
studied by SEM and EDX. The results can not only reveal the rule of MNP loading in 
fibre, but also improve the design of the mixture.  
Furthermore, for different applications, a better selection of concentration can be 
made. Fibres made from both PVA and PVA-MNP appeared to have a distribution of 
100-300 nm in diameter determined by ImageJ (Figure 5-4-Figure 5-7).  
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Figure 5-4 SEM images of pure PVA fibres. 
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Figure 5-5 SEM images of 3%(wt) PVA-MNP fibres. 
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Figure 5-6 SEM images of 4%(wt) PVA-MNP fibres. 
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Figure 5-7 SEM images of 5%(wt) PVA-MNP fibres.
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5.4 EDX Analysis  
5.4.1 Element dot mapping 
The incorporation of Fe3O4 MNPs into the fibres was visualized via EDX dot mapping, 
which can reveal if the iron oxide powder is distributed homogeneously on the fibres. 
Apart from Fe, C, O and S are also taken in element analysis as a reference. The 
white dots on the black background represent their position compared with SEM image 
in the same area.  
 
Figure 5-8 SEM-EDX dot mapping images. Pure PVA fibres.  
To indicate the presence of Fe element (from Fe3O4) on selected areas of samples, 
the spectroscopy system needs to run more times (10-15) on the same area to detect 
clear elements for dot mapping because even for 5% (wt) PVA-MNP fibres, the content 
level of Fe is low from the whole sample background for the analysis system used. 
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However, due to the system sensitivity, too many repeating scans cause a lot of noise 
on mapping which becomes an error in the image (Figure 5-8 -Figure 5-14).  
Four samples were analysed for test and future selection which are pure PVA fibres, 
3% (wt) PVA-MNP fibres, 4% (wt) PVA-MNP fibres and 5% (wt) PVA-MNP fibres. As 
MNPs percentage in PVA increases, their behaviour on EDX analysis changes which 
are to be studied and if the trend exists, the improved design of fibre composition can 
be used for future experiment.  
Pure PVA fibres are done first for a comparison as the control sample to others (Figure 
5-8). Because without Fe, the sample should give no response to the Fe element. For 
the Fe element dot mapping on the top right of Figure 5-4, the nearly pure darkness 
confirms pure PVA fibres have no Fe can be speculated. 
 
Figure 5-9 SEM-EDX dot mapping images. 3%(wt) PVA-MNP fibres (a). 
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Figure 5-10 SEM-EDX dot mapping images. 3%(wt) PVA-MNP fibres (b). 
 
 
Figure 5-11 SEM-EDX dot mapping images. 4%(wt) PVA-MNP fibres (a). 
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Figure 5-12 SEM-EDX dot mapping images. 4%(wt) PVA-MNP fibres (b). 
 
 
Figure 5-13 SEM-EDX dot mapping images. 5%(wt) PVA-MNP fibres (a). 
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Figure 5-14 SEM-EDX dot mapping images. 5%(wt) PVA-MNP fibres (b). 
C, O and S act normally as they are mostly from the background but C and O show 
more information because PVA has C and O which may show concentration in the 
images if the fibres are constructing a shape. S is from the electric conductive sticker 
used for fixing the sample on the metal base for SEM. Therefore, S should always 
show an average dispersion on mapping.  
For 3% (wt) PVA-MNP fibres, the results show that the Fe element exists (Figure 
5-9,Figure 5-10). However, the weak signal, due to low Fe concentration for the sample, 
causes the dots to be mapped not in the position as coming along with fibres in SEM 
image. As a comparison, 4% (wt) ones are better on performance which the red arrows 
in the images indicate the dot group giving a stronger response (Figure 5-11,Figure 
5-12). This also accords with the principle that more MNPs are added to the PVA 
solution and more MNPs will be loaded into final fibres.  
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Figure 5-15 SEM dot mapping: red dots indicate the presence of Fe in fibres (a). 
 
Figure 5-16 SEM dot mapping: red dots indicate the presence of Fe in fibres (b). 
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Figure 5-17 SEM dot mapping: red dots indicate the presence of Fe in fibres (c). 
The 5% (wt) sample (with red arrow and guidance line) supports this principle by 
showing the dots in a pattern compared to fibres themselves from SEM images (Figure 
5-13,Figure 5-14). Moreover, C and O element dot mapping results are a good 
reference for this pattern.  
As can be seen, with the weight percentage of MNP increasing from 3% to 5%, the 
number of dots from corresponding SEM-EDX mapping images also increases. 
Although due to the capacity of element detecting, the instrument delivers much noise 
to the final results, the loading of MNPs on PVA fibres is confirmed. For a better 
demonstration of the Fe element in existing positions in the scanning area, another 
three mapping functions were run by EDX program on 5% (wt) PVA-MNP because of 
its higher-level response. Those images show the combination of Fe (red dots) and 
sample SEM image (Figure 5-15 - Figure 5-17).  
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5.4.2 Surface elemental analysis  
To detect a more specific volume of Fe on PVA-MNP fibres, the surface elemental 
analysis using EDX was done, where the selected area of fibre sample subject to EDX 
analysis was studied. 
The samples for EDX are all placed on the sticker designed for microscopy and 
spectroscopy. To exclude the interference of the elements of the sticker, a blank area 
scan for the pure sticker with the same carbon coating as fibre samples was done 
(Figure 5-18). The sticker has Na, S, O and C (C is removed from the list in the figures 
by a software setting because of carbon coating) as main elements, therefore these 
elements will also appear in fibre sample results of EDX.  
 
Figure 5-18 SEM-EDX images. Sticker.  
To study the effect of different MNPs weight percentage solution mixture on MNPs’ 
actual loading on the final product, four PVA-MNP fibre samples (with MNPs 
concentration increasing in PVA solution for spinning) are used as in the former 
section.   
The pure PVA (0%) fibre sample is for control. 3%(wt), 4%(wt) and 5%(wt) PVA-MNP 
fibres were made forming progressive levels for analysis. All samples were studied in 
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the same condition. For each sample, three different areas, which are general fibre 
area, the fibre bead and the fibres in the same area near the bead, were fully 
characterised to get the volume of Fe loaded. Moreover, three areas rather than one 
can reduce the error of the area selection factor (Figure 5-19 - Figure 5-30). Red arrows 
are drawn in the spectrum images indicating Fe peak. The Fe element was also 
highlighted in the table of element analysis with its concentration.  
 
Figure 5-19 SEM-EDX images. Pure PVA (a). 
 
Figure 5-20 SEM-EDX images. Pure PVA (b). 
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Figure 5-21 SEM-EDX images. Pure PVA (c). 
 
Figure 5-22 SEM-EDX images. 3%(wt) PVA-MNP fibres (a). 
 
Figure 5-23 SEM-EDX images. 3%(wt) PVA-MNP fibres (b). 
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Figure 5-24 SEM-EDX images. 3%(wt) PVA-MNP fibres (c). 
 
Figure 5-25 SEM-EDX images. 4%(wt) PVA-MNP fibres (a). 
 
Figure 5-26 SEM-EDX images. 4%(wt) PVA-MNP fibres (b). 
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Figure 5-27 SEM-EDX images. 4%(wt) PVA-MNP fibres (c).  
 
Figure 5-28 SEM-EDX images. 5%(wt) PVA-MNP fibres (a). 
 
Figure 5-29 SEM-EDX images. 5%(wt) PVA-MNP fibres (b).  
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Figure 5-30 SEM-EDX images. 5%(wt) PVA-MNP fibres (c).  
The presence of surface Fe was successfully detected using EDX. For 3%(wt) PVA-
MNP sample, the recorded readings of Fe weight percent are 6.72% and 9.68% on 
fibres, and 8.06% on bead. Beads Fe content for 4%(wt) and 5%(wt) is 20.38% and 
19.81%. Fibre area Fe content for 4%(wt) shows 13.37% and 12.74%. This content 
becomes 16.06% and 8.84% for 5%(wt). The beads have higher Fe volume because 
beads have larger thickness giving more materials, but this is not much more than in 
fibres which means the dispersion of MNPs in the whole fibre sample is quite average. 
The average Fe loading volume in fibres for 4%(wt) is close to 5%(wt). As stated in 
the former section, 5%(wt) solution making in practice is close to the limit of the 
mixture. Higher (over 5%) additional volume of MNPs to the PVA solution cannot make 
the absorption better. Therefore, MNPs loading to fibres can be increased by adding 
more MNPs into PVA solution during preparation. However, 5%(wt) is the restriction 
for not exceeding the limit of the PVA-water system which is important because this 
information can be used for solution design and preparation. As 5%(wt) may apply the 
most loading of MNPs which deliver stronger magnetism and do not break the mixture, 
it was chosen to be used for the following test of controlled fibre moving and drug 
release.   
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5.6 FTIR 
The typical peaks for PVA and citric acid were identified through FTIR (Figure 5.33). 
These include the broad peaks at: 3300 cm-1 from the stretching mode of inter- and 
intra- molecular hydrogen bonds of O–H; 2920 cm-1 and 2850 cm-1 from the C–H 
vibrational mode of alkyl groups; 1735 cm-1 from the stretching mode of C=O of the 
carbonyl groups; 1085 cm-1 from the C–O–C stretching mode; a shoulder at ~1141 
cm-1 from C–O stretching of crystalline PVA; and, at 1242 cm-1, from the symmetric 
stretching mode of citric acid142–144.  
 
Figure 5-31 FTIR spectrum. 
Figure 5.33. Characterization of chemical composition and magnetic content of the 
PVA-MNP fibres. (A) FTIR spectrum.  
However, the characteristic vibrational bands of Fe3O4, usually found at 634, 582 and 
397 cm-1 characteristic of magnetite145 were not discernible via the instrument used.  
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5.7 SQUID analysis  
The SQUID analysis is to measure the magnetization of the materials tested, through 
which, the MNPs amount in the fibres can be determined. It was found that the fibres 
were comprised of 4.9 % magnetic component by weight (due to Fe3O4 MNPs), as 
determined by the fraction of the mass magnetization for the PVA-MNP fibres (M = 2.6 
Am2kg-1) and the pure MNP nanoparticles (M = 53.8 Am2kg-1) (Figure 5-32).  
Since the polymer solution fed to the spinning apparatus consisted of 5 % of MNPs by 
weight, this shows that the process of infusion gyration is highly effective in generating 
fibres with minimal loss of the magnetic material.  
 
 
Figure 5-32 Mass magnetization behaviour of (a) both pure MNP and 5%(wt) MNP-PVA fibre samples, (b) 5%(wt) 
MNP-PVA fibre samples.   
 
This observation, coupled with the previously investigated efficacy of the gyration 
process133 renders the potential for scaled up production of magnetic fibres using 
this technique.   
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5.8 Optical Microscopy 
Optical microscopy revealed a fibre matrix containing small amounts of beads 
distributed in the matrix, for both pure PVA (Figure 5-33) and PVA-MNP (Figure 5-34) 
samples. The general fibre structure with three scales were observed and recorded.  
 
Figure 5-33 Optical microscope images. Pure PVA.  
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Figure 5-34 Optical microscope images. 5%(wt) PVA-MNP fibres.  
The pure PVA fibres show transparent structure and PVA-MNP ones are darker 
along the fibre which is because it loads the MNPs.  
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5.9 Drug Release Experiment  
Acetaminophen was effectively immobilized onto the PVA-MNP fibres, following 
which, the drug-fibre system was transferred to an absolute ethanol medium and 
studied for the release of acetaminophen with time, both with and without magnetic 
actuation. Separate experiments were conducted in duplicate, for the control (i.e., 
without actuation) and actuated studies.  
Samples were taken out at relevant time intervals (1min for the first 5 and 5min for the 
rest until 30min complete) and subject to UV-Vis analysis. The ethanol volume was 
kept constant for all samples throughout the study by replacing the sampling volume. 
The fibres effectively responded to the external magnetic field, while contained in glass 
vials open to the air, or in glass vials containing absolute ethanol (Figure 5-35). The 
fibres could also easily be guided in a channel containing ethanol (Figure 5-36).  
 
Figure 5-35 Procedure for magnetic actuation of fibres loaded with acetaminophen. 
Chapter 5 
159 
The ability to release controlled quantities of drugs via application of an external 
stimulus onto the carrier platform is a highly advantageous feature for drug delivery. 
This was successfully demonstrated by the controlled release of acetaminophen 
loaded on the PVA-MNP fibres, via an external magnetic field. Absolute ethanol was 
chosen as the medium for these experiments, in which the magnetic fibres were 
stable. 
 
Figure 5-36 Transportation of the magnetic fibres along a tube, using magnetic actuation, demonstrating the 
scope of actuation.  
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5.9.1 UV-Vis & release study  
 
Figure 5-37 MNP leaching studies for PVA-MNP fibres conducted via UV-Vis absorbance of supernatant solutions 
of the following: (A) 5 % (w/v) MNPs dispersed in ethanol, (B) 5 % PVA-MNP fibres stored in ethanol for 4 weeks, 
(C) Ethanol (blank).  
UV-Vis experiments conducted on the supernatant of PVA-MNP fibres stored in 
absolute ethanol for 4 weeks, showed no traces of Fe3O4 leaching which confirms the 
stability of the composite fibres (Figure 5-37).  
Acetaminophen has strong UV absorption with a prominent peak at 243 nm and a 
broad shoulder around 290 nm, in water146. In absolute ethanol these peaks were 
observed at 248 nm and 295 nm, respectively (Figure 5-38).  
A calibration curve for acetaminophen was obtained using standard solutions and was 
used to determine the concentration of its quantities released during the control and 
actuation experiments of the acetaminophen loaded fibre system (Figure 5-39).  
Based on the above results, the concentration and the cumulative % of acetaminophen 
released were plotted against time (Figure 5-40 and Figure 5-41, respectively).  
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Figure 5-38 Chemical structure and UV-Vis absorption spectrum of acetaminophen.  
 
Figure 5-39 Calibration curve for acetaminophen, prepared at a 100x dilution.  
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Figure 5-40 Concentration of acetaminophen released with time. 
 
Figure 5-41 Cumulative weight percentages of acetaminophen released with time. The control experiment 
represents the equivalent release of acetaminophen without magnetic (or any other type of) actuation.  
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It was evident that the magnetically actuated fibre system released significantly more 
acetaminophen with time, compared to the non-actuated system. For the actuated 
samples, a rapid release of acetaminophen was observed during the first 5 min, 
followed by a gradual increase, up to 15 min, following which the release plateaued 
until the 30-min experimental time frame.  
This behaviour is consistent with a ‘burst-release’ mechanism147. Over 90 % of the 
drug is already released by the end of 15 min of actuation, and the release appeared 
to be slightly reduced after this point. A possible explanation for the above is that the 
drug release had stopped due to entrapment of the remaining drug within the fibre 
matrix, resulting in an overall reduction of concentration. Hence, the drug release 
based on magnetic actuation appears to consist of two main phases: a 5-min initial 
burst release, and then a relatively slower but steady release up to 15 min.  
 
Figure 5-42 Effect of magnetic actuation on drug release with time: the difference between actuated and non-
actuated cumulative release curves.  
It is also noteworthy that since the drug release is triggered by movement (i.e., 
magnetic actuation), the acetaminophen concentration cannot be ensured 
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homogeneous throughout the test solution. This may result in greater differences in 
duplicate experiments conducted for actuated samples compared to the controls, 
hence, bringing about larger experimental errors for the former. In contrast, the control 
samples released significantly lower amounts of drug during the first 5 min, followed 
by a slower gradual increase of drug release over the next 20 min, and finally showing 
a slight decrease in the last 5 min. This behaviour can be attributed to simple diffusion 
of the immobilized acetaminophen powder from the fibre network.  
The difference between the cumulative % of acetaminophen released over time, from 
the actuated and control experiments is depicted in Figure 5-42. By the end of the first 
5 min, approximately 71 % of acetaminophen is released, compared to the control, 
followed by a decreased, yet steady difference up to 15 min, and even smaller 
differences by the end of 30 min. This is clear evidence that remote magnetic actuation 
can bring about significant release of drugs from the PVA-MNP fibres.  
 
5.9.2 Summary  
Based on the above results, it is evident that the PVA-MNP fibres are capable of fast 
drug release during smaller time scales and slower, consistent rates of drug release 
over time, via magnetic actuation. This novel, biocompatible, cost effective and 
controllable technique has the potential to be used clinically, as an effective tool for 
triggered drug release. Application of this mode of drug delivery is particularly 
attractive in wound care, due to several reasons: 1) it can be used in the community 
by tissue viability nurses, 2) repeated drug delivery can be effected, without 
necessarily changing or removing the dressings, 3) chemical debridement of wounds 
(as opposed to surgical debridement for which one needs an anaesthetic, theatre time 
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and, often, a physician to conduct the procedure) can be carried out if the relevant 
drug is incorporated into the PVA-MNP fibres. Moreover, there is increasingly a focus 
to move the management of wound care into the community, which achieves two 
important NHS objectives: (a) it relieves hospital bed pressures, and (b) patients can 
be managed in the convenience of their own homes, and are not subjected to the 
challenges of being an in-patient.  
This technology also has potential applications for “site-specific” treatment, due to its 
customizable properties. For example, the sensitivity of magnetic actuation of the 
fibres, namely, the minimum depth and distance from the magnetic source needed for 
actuation, can be improved by either increasing the MNP concentration or the power 
of the magnet. Then, the material can possibly be applied in treatment of 
atherosclerotic plaque in the carotid artery, or, in simpler terms, for prevention of a 
stroke. In this instance, the magnetic fibres could be administered intravenously, and 
then the magnetic actuation could be directed to the carotid artery in the neck, so that 
the drug would be released only at this specific site. If deeper penetration of the 
magnetic force can be achieved safely, then one could envisage widening the portfolio 
of use within the body, in a number of conditions, for example, acute conditions such 
as sepsis, and chronic diseases, such as inflammation in arthritis, inflammatory bowel 
disease, and in a range of oncological therapies. 
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Chapter 6.  
Infusion gyration analysis  
6.1 Set-up Analysis   
The infusion gyration system is developed from the gyration system. For each gyration 
system, an infilling tube on top of the cap is designed either delivering continuous gas 
pressure which forms pressurised gyration which was introduced in Chapter 2 or 
continuous spinning solution at some flow rate which forms infusion gyration.  
Regarding Figure 6-1 of the fibre spinning gyration system, the whole system can be 
treated as functional blocks combined in a different way. For example, if we choose 
pressure block and gyration block, it is pressurised gyration.  
 
Figure 6-1 Analysis of gyration system. 
A high-pressure nitrogen supply is used because of its low cost and nitrogen barely 
reacts with chemicals which may be a kind of protection to the spinning solution. If the 
experiment requires low complexity of its surrounding, nitrogen provides a purer gas 
environment for the spinning process. Moreover, this gas supply can vary depending 
Chapter 6 
167 
on other experiment designs. If a new design requires another gas environment 
because the solution needs the reaction with the specific gas during the spinning 
process, the nitrogen cylinder can be replaced by hydrogen or oxygen. Or, if the 
solution is safe to the air, which means the solution only requires pressure, a stable 
air turbocharger with enough pressure providing capacity is also acceptable. Here, the 
important thing is that any kind of gas supply affects the environment outside around 
the pot. In this small area, humidity and temperature change quickly in a short time. 
Any gas supply change should be tested to narrow down the effect on the spinning 
process unless the effect is needed.  
However, the solution needs to be added into the vessel prior to spin because the gas 
supply occupies the inlet from the pressurised gyration system to deliver pressure to 
the cylindrical vessel. Therefore, the volume of solution should be considered and the 
run is a start-stop process which means if every part is fixed preparing for a start, the 
change must be made after spinning completion.  
Furthermore, solutions can also be spun at 0 gas pressure revealing the fact that 
rotation is the main power driving the formation of fibres. The results from Chapter 2 
also confirms that gas pressure was used as a tuning tool of fibre shape.  
The idea of inventing a novel infusion gyration system is to simplify the spinning 
process such as solution adding and to control the solution supply in order to control 
the spun fibre properties.  
6.2 Time Analysis 
Time is an important factor in laboratory experiment or industrial manufacturing. The 
time analysis of experiment completion is made from experiment experience which 
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provides recommendations of experiment planning (time control of completing 
experiment) and improvement in the future (Table 6-1).   
Step  Actions  Time  
1 Solution preparation. Some solution needs a 
longer time to dissolve.  
Depends.  
2 Set-up preparation including electric connection, 
tube connections, screws and seals.  
~15min. 
3 Trial. This may be done several times ensuring 
system is working well.  
~5min. 
4 Syringe pump setting and syringe preparation ~5min. 
5 Spinning session (start to finish).  ~10min. 
6 Solution refill. ~2min. 
7 Cleaning.  ~15min. 
Table 6-1 Time analysis of infusion gyration. 
Step 5 and 6 can be repeated if needed. The preparing and cleaning process take 
most of experiment time except for solution making and spinning repeats.   
 
 
6.3 Fibre Formation analysis   
The centrifugal force driving the solution into tiny streams through orifices is from high 
speed rotating cylindrical vessel (Figure 6-2).  
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Figure 6-2 Centrifugal force.  
This force directly relates to rotational speed (n) of the vessel driven by the motor. 
Here, in calculation, the unit rpm needs to transfer to rad/s. For pressurised gyration 
introduced in the literature review, the centrifugal force also combines to the force from 
gas pressure (P, Pa in unit) which is supplied by the system where S (m2) is cross-
section area of the orifice.  
Fgas pressure =  
𝑃
𝑆
 
When the stream is accelerated, it has the velocity to fly and stretch. The stream 
becomes thinner and longer at this stage (Figure 6-3).  
 
Figure 6-3 Stream stretching.  
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In this process, the solvent evaporates as well as the fibre forms (Figure 6-4). The 
formation of different fibre shape occurs in this stage connecting to the evaporation 
rate which is affected by polymer, solvent, concentration and environmental humidity.  
 
Figure 6-4 Fibre formation.  
However, due to the difference of solution property (such as viscosity and surface 
tension), different formation happens to the stream. Some stream breaks before it gets 
thinner (Figure 6-5).  
 
Figure 6-5 Stream break. 
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These broken streams either form large diameter fibres or form beads if the 
evaporation is slow (because surface tension directs liquid into a spherical structure).  
6.4 Balance Point Conjecture 
The ‘strange point’ of flow rate, which was introduced in Chapter 4, happens in the 
infusion gyration process. The average diameter of fibres decreases at some point at 
a flow rate in between a lower one and a higher one. Three repeats of experiment 
resulted the same. If the parameter changes from flow rate to pressure, the point 
cannot be observed any more (the pressurised gyration shows linear result5). This is 
because the pressure may only assist the centrifugal force to project by providing more 
pushing power. Moreover, the solution is all added prior to spin for pressurised 
gyration and the gas may influence the evaporation rate. These factors are all for 
stretching the stream.  
However, as we control the flow rate in the process, the stream can no longer stretch 
freely. For infusion gyration, the centrifugal force is a constant value, if the rotating 
speed of the vessel is stable, which accelerates the stream to a velocity at early flying 
stage. If we multiply this velocity by the stream cross section area, we get another 
‘flow rate’ value which is defined by volume over time. However, the initial flow rate 
(stream with velocity) is supplied and controlled by the infusion system. These two 
values exist in one continuous stream which would also cause stretch or press on itself 
influencing the fibre size. In other words, the infusion system can drag or push the 
flying stream from one side during spinning. At lower flow rate, all solution is spun into 
fibres as they have a smaller size. At higher flow rate, breaks decrease but more mass 
into the stream causes larger fibre size. However, in between, there is always a point, 
i.e. ‘balance point’, whose supply equals to the stretching mass which will extend the 
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fibre length to its limit. This point delivers a lower diameter of fibres which differs from 
polymer, solution concentration and other parameters.  
6.5 Products  
6.5.1 PVA fibres   
In chapter 5, high magnification SEM of PVA-MNP fibres was studied. Here, images 
of a much lower one were taken for comparison (Figure 6-6 - Figure 6-9). Beads are 
observed within fibres with different size which were also recorded in optical 
microscopy images in Chapter 5. The content of MNPs does not obviously affect fibre 
morphology in large scale which accords with the results of high magnification images 
close-up to the single fibres. 
 
Figure 6-6 SEM images of pure PVA fibres. 
 
Figure 6-7 SEM images of 3%wt MNPs PVA fibres. 
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Figure 6-8 SEM images of 4%wt MNPs PVA fibres. 
 
Figure 6-9 SEM images of 5%wt MNPs PVA fibres. 
Beads existing in the final generated fibres by different method are quite common and 
they come along with the fibre formation process99. Some application may make use 
of them because of their properties such as increasing the loading or attaching ability 
of other media, for example.  
 
6.5.2 PVA & PEO fibre comparison  
Both as water soluble polymer successfully spun by infusion gyration, the morphology 
comparison of two fibres through SEM images can point out their similarities and 
difference providing recommendations for spinning other polymers in the future (Table 
6-2).   
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PVA fibres PEO fibres 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-2 SEM image comparison for PVA and PEO fibres. 
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From the comparison above, similar fibre size of them is observed and differences can 
be concluded as follows.  
1. PVA fibres have more beads than PEO ones in general.  
2. PVA fibre is smooth on its surface, however, it is rough for PEO.  
3. PVA fibre tends to be straight. PEO fibre is curlier.  
4. PVA fibres form a net structure. PEO fibre stands alone.  
Therefore, the number of beads (or beads formation), fibre surface roughness and 
shape will not affect the fabrication process of infusion gyration. Polymer can be 
changed for controlling these factors depending on product requirement and 
application. Infusion gyration also has a potential of adapting different polymers.  
 
6.5.3 PAN fibres   
To test the capacity of infusion gyration spinning non-water-soluble polymer fulfilling 
the waterproof requirement for possible future applications, polyacrylonitrile (PAN) 
which does not dissolve in water but in strong solvent has been tried. PAN 
(polyacrylonitrile, 150,000 typical average molecular weight) powder and DMF (N,N-
Dimethylformamide) solvent used are from Sigma-Aldrich (Poole, UK).  
10wt% PAN-DMF solution was prepared for spinning:  
18g of DMF was prepared in an air-tight glass bottle as solvent and 2g of PAN powder 
was added in the bottle. The solution was shaken for full mixture and kept stirring for 
no less than 48hrs until PAN powder is fully dissolved. 20g 10wt% PAN-DMF 
transparent solution was made. 5ml 10wt% PAN-DMF solution was added into a 
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syringe fixed on a syringe pump and spun by infusion gyration. Spinning speed was 
set to 36,000rpm and infusion flow rate was 2000ul/min. Spinning time is 3min and 
after spinning was stopped, the fibres were kept on aluminium foils for 10min to dry 
the fibres. Then the fibres were collected for SEM (Figure 6-10).  
 
Figure 6-10 SEM images of PAN fibres. 
The fibre surface is smooth and beads were not observed for PAN fibre sample which 
means bead-free waterproof fibre can be made through infusion gyration. This 
successful spinning of PAN fibres also broadens the type range of materials this 
method can process. Moreover, these polymers with different properties would serve 
more applications of fibre.  
6.5.4 Microbubbles  
In Chapter 2, it has been reported that polymer microbubbles can be generated 
through pressurised gyration. To gain the flexibility of infusion gyration, trial of 
microbubble production was applied.  
5wt% PVA (Mw 31000) aqueous solution was prepared. The flow rate was set to be 
6000 µl/min which is higher than usual mimicking the status of sufficient solution which 
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pressurised gyration provides. The rotating speed was kept the same as before on 
36,000rpm. Microscope slides were placed on the inner wall of the spinning container. 
They were immediately transferred and observed after production, under an optical 
microscope (Nikon Eclipse ME 600) fitted with a camera (JVC KY-F55B). Images are 
as follows (Figure 6-11).  
 
Figure 6-11 Microbubble generation by infusion gyration. 
 
Figure 6-12 Products by infusion gyration.  
It is seen that microbubbles were well formed and delivered by infusion gyration which 
extends the product range proving its high flexible process ability (Figure 6-12).   
Chapter 7 
178 
Chapter 7.  
Conclusions and Future work  
7.1 Conclusions  
Micro and nano fibres composed of nano-assemblies show great promise as enabling 
constituents for diverse applications in areas ranging from tissue engineering, sensing, 
optoelectronics and nanophotonic devices due to their controlled organisation and 
architecture. This thesis provides an infusion gyration method that enabled a bio-
fabrication process to form functional micro/nanofibres with inherent biological 
functions. This method (detailed in Chapter 3) allows tuning both the fibre size and 
distribution by adjusting the flow rate of the polymer solution without using an external 
pressure. The results have multiple implications.  
In chapter 4, PEO fibre coupled engineered protein has been made showing 
fluorescence which is designed as the fibre function. A power law relationship between 
the polymer concentration and its viscosity, as well as a relationship between the Berry 
number (Be) and the formed structures are the principles that guide the formation of 
fibres. A sufficient amount of chain entanglement was obtained at Be > 1.6 for fibres 
integrated with proteins having 117-216 nm diameter range. Fibre morphology 
evaluated by field emission scanning electron microscopy demonstrated well fibre 
formation. The effects of processing parameters on fibre size, size distribution and 
morphology are analysed. Fluorescence microscopy analysis corroborated with FTIR 
data confirmed the integration of the engineered gold binding peptide within the fibres. 
The compatibility of proteins into fibres was tested. The assembly of the engineered 
proteins as an integrated part of the fibre could be followed using fluorescence protein. 
The integration of biological building blocks i.e. functional proteins and peptides to 
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fibre processing may allow harnessing the extraordinary diversity afforded by protein 
functions to generate smart bio-hybrid materials for imaging, bioelectronics, bio-
sensing and tissue engineering applications.  
In chapter 5, a new experimental system of controlled drug release was introduced. A 
PVA mixture ratio for infusion gyration was found. PVA fibres with iron oxide 
nanoparticles incorporated were prepared through this method which has been tested 
as potential for industrial mass production. From the SEM, EDX and other 
characterization method results, the nanoparticles are bonded into polymer structures 
as aggregation and dispersed in fibres uniformly. These fibres with sufficient 
magnetization can be noncontact controlled for movement and actuation showing 
strong magnetic field response via external magnets. They were shown to be stable 
when stored in ethanol, without any leaching of iron oxide nanoparticles. Moreover, 
the spongy structure of fibre mass is a good absorbent for drugs. This fibre with its 
magnetic activity shows great potential of target-controlled and sustained drug release 
for bio-medical purpose such as treatment of wound healing. An approach has been 
established in laboratory conditions to demonstrate the concept of controlled drug 
release. Acetaminophen, as a model drug used, was successfully released from the 
fibres when subject to magnetic actuation, bringing about over 90 % cumulative 
release in 15 min. Compared to non-actuated controls, the magnetic fibres showed 
over 71 % more release of the drug within 15 minutes, so the utility of the new drug 
delivery and controllable release platform has been illustrated. The above, coupled 
together with the facile, cost effective material synthesis, with proven ability to scale 
up, offers attractive opportunities in clinical application of the magnetic fibres.   
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In Chapter 6, a detailed analysis for an infusion gyration system is made theoretically 
and practically. A conjecture was proposed to explain the phenomenon which 
happened during the process. Different products were studied.  
 
 
7.2 Future Work  
Excellent functional composite micro/nanofibres have been made for potential 
applications and the novel infusion gyration system invented has demonstrated the 
capacity of generating products under control. As far as can be established by the 
whole functional fibre spinning using an infusion gyration experience, improvement 
can be made in two main parts.  
1. If we face the product object, i.e., we would like to achieve some functions, 
objectives and application in practice on the fibres themselves, we can test and 
change the type of polymer as well as the different solvent system or functional 
adoptions.  
2. If we face the generation process, i.e., we would like to increase the yield of 
production and improve the fibre shape, we can tune the parameters of the set-
up such as flow rate and motor speed or even add other new parameters like 
temperature control to the system. 
Therefore, by following these two key principles, these aspects of recommendations 
for the future work are as follows.  
Chapter 7 
181 
7.2.1 Change of the engineered protein  
The integration of fluorescence protein to the fibres using an infusion gyration process 
demonstrates that the engineered proteins (i.e. biological building blocks) can 
contribute to bio-hybrid fibre formation by providing control over nanoscale 
assemblies. Fluorescence protein has a potential for bio-sensing as it is easy to track 
by fluorescence microscopy which, on the other hand, helped the trial in this study. 
Nevertheless, other engineered proteins with functions can be used in fibre spinning 
to achieve another kind of functional fibres, even different proteins are mixed. 
Therefore, designed functional bio-material may be performed by changing the 
engineered protein mixed to polymer solution.  
 
7.2.1 Drug release test in-vivo 
The PVA-MNP fibres used in the drug release test shows a good performance. 
However, it is just a validation of drug delivery. More planned tests of drug release 
experiment can be done to make the fibres closer to clinical application. The material 
(polymer and drug) can be changed (to a non-water-soluble one, for example) for the 
other areas extended by this system for different purposes.  
 
7.2.2 PVA mixture theory developing 
An important and interesting finding is that, for infusion gyration, only the mixture of 
three different PVA molecular weights in a specific ratio can deliver a higher volume 
of fibres during formation. One possible reason is that the crosslink occurs between 
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the chemical chains of the different size of PVA macromolecular. Research has been 
made to chitosan hydrogels on crosslinking network structure148 (Figure 7-1).  
 
Figure 7-1 Schematic of chitosan hydrogel structure types148. 
Therefore, the theory of PVA mixing can be studied and developed to gain a better 
understanding of polymer fibre formation. Topology may be a useful mathematical tool 
for analysing as ‘knot theory’ is to study patterns of rope structure (which may have a 
similarity with a chemical chain) knotting, binding and attaching. Energy can also be a 
factor to be considered.  
 
7.2.3 Study of infusion gyration 
More polymers can be tested generating fibres through this method at a different flow 
rate. The relationship between fibre properties and spinning parameters can be 
concentrated for production and research in the future.  
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7.2.4 New system design 
A better clean and closed protection collection system can be designed to improve the 
quality control of fibres. If a small climate control system is applied to the infusion 
gyration, the temperature, humidity and air flow can be purified and kept constant to 
reduce disturbance of the fibre formation. Moreover, the modularity can be enhanced 
if function block design is introduced. For example, a different performance motor or 
a collector can be changed for a different project and the collection distance can be 
modified every time which tunes the forming space. This design shortens the time 
span of experiment and even the repair sometimes which means changing or 
replacing parts is rapid. Even new function blocks for this system can be developed to 
improve the capacity for other applications.  
 
7.2.4.1 New flow supply  
Using a shunt connector can provide more flexibilities to the system (Figure 7-2). 
 
Figure 7-2 Shunt connector.  
Application 1: Fast shifting syringes (Figure 7-3). Through this method, a solution can 
be quickly refilled to the system doubling the volume of solution spun once and 
shortening refill time. When one syringe finishes a solution, the system is stopped to 
fix another into position.  
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Figure 7-3 Fast shifting syringes by shunt connector.  
Application 2: Combining spinning solutions. Two liquids can be mixed (in different 
ratio) when delivered to the cylindrical vessel if the liquid requires mechanical mixture 
to spin in a very short time (like oil phase and water phase). In addition, mixed fibres 
may be spun through it where the composite material can be designed and made.  
This idea can extend to three or more solutions mixing during spinning which may 
need more syringes system. Sometimes, more syringe pumps (like double pumps) are 
not essential for these systems as some syringe pump has an adaptor for multiple 
syringe. A continuous flow supply can be applied to manufacturing in industry.  
 
7.2.4.2 New rotating part 
The cylindrical vessel used can apply new dimensions such as diameter and orifice 
size. The guiding groove design inside the vessel can improve solution streams to the 
orifice if machining allows. An easy-to-clean design is required.  
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